TWI555747B - ２－（１，２，３－三唑－２－基）苯甲醯胺及３－（１，２，３－三唑－２－基）吡啶醯胺衍生物 - Google Patents

Info

Publication number

TWI555747B

TWI555747B TW101141421A TW101141421A TWI555747B TW I555747 B TWI555747 B TW I555747B TW 101141421 A TW101141421 A TW 101141421A TW 101141421 A TW101141421 A TW 101141421A TW I555747 B TWI555747 B TW I555747B

Authority

TW

Taiwan

Prior art keywords

triazol

benzyl

phenyl

methanone

morpholin

Prior art date

2011-11-08

Links

• Espacenet
• Global Dossier
• Discuss

• TYWGXVSIWUAVQS-UHFFFAOYSA-N 2-(triazol-2-yl)benzamide Chemical compound NC(=O)C1=CC=CC=C1N1N=CC=N1 TYWGXVSIWUAVQS-UHFFFAOYSA-N 0.000 title description 4
• NJRYJHSCUMBRAM-UHFFFAOYSA-N 3-(triazol-2-yl)pyridine Chemical class N1=CC=NN1C1=CC=CN=C1 NJRYJHSCUMBRAM-UHFFFAOYSA-N 0.000 title description 3
• 150000001875 compounds Chemical class 0.000 claims description 282
• -1 methoxy, hydroxy Chemical group 0.000 claims description 69
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 54
• 239000001257 hydrogen Substances 0.000 claims description 53
• 229910052739 hydrogen Inorganic materials 0.000 claims description 53
• 125000000217 alkyl group Chemical group 0.000 claims description 34
• 150000003839 salts Chemical class 0.000 claims description 31
• 229910052736 halogen Inorganic materials 0.000 claims description 27
• 150000002367 halogens Chemical class 0.000 claims description 27
• 150000002431 hydrogen Chemical class 0.000 claims description 27
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
• 238000011282 treatment Methods 0.000 claims description 24
• 239000000460 chlorine Substances 0.000 claims description 23
• 208000019901 Anxiety disease Diseases 0.000 claims description 21
• 206010012335 Dependence Diseases 0.000 claims description 20
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 19
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 17
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
• 125000001153 fluoro group Chemical group F* 0.000 claims description 16
• 125000001424 substituent group Chemical group 0.000 claims description 16
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
• 201000010099 disease Diseases 0.000 claims description 14
• 125000003709 fluoroalkyl group Chemical group 0.000 claims description 14
• 125000004432 carbon atom Chemical group C* 0.000 claims description 13
• 239000003814 drug Substances 0.000 claims description 13
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 12
• 230000036506 anxiety Effects 0.000 claims description 12
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
• 208000019022 Mood disease Diseases 0.000 claims description 10
• 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 10
• 125000001072 heteroaryl group Chemical group 0.000 claims description 10
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 9
• 125000001715 oxadiazolyl group Chemical group 0.000 claims description 9
• 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims description 9
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 9
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
• 125000001425 triazolyl group Chemical group 0.000 claims description 9
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
• 229910052801 chlorine Inorganic materials 0.000 claims description 8
• 125000003373 pyrazinyl group Chemical group 0.000 claims description 8
• 125000002098 pyridazinyl group Chemical group 0.000 claims description 8
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 8
• 125000001544 thienyl group Chemical group 0.000 claims description 8
• 125000002971 oxazolyl group Chemical group 0.000 claims description 7
• 125000004076 pyridyl group Chemical group 0.000 claims description 7
• 125000000335 thiazolyl group Chemical group 0.000 claims description 7
• 208000027559 Appetite disease Diseases 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 6
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
• GKPHAIOJCHBZCT-HXUWFJFHSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 GKPHAIOJCHBZCT-HXUWFJFHSA-N 0.000 claims description 4
• 208000017194 Affective disease Diseases 0.000 claims description 3
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 3
• RDSLXYSTWOTMMZ-HXUWFJFHSA-N [(3R)-3-[(4-methyl-3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound CC1=C(C=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C1)C1=NC=CC=N1 RDSLXYSTWOTMMZ-HXUWFJFHSA-N 0.000 claims description 3
• CXGGFUAERWUYLI-GOSISDBHSA-N [(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)-4-(trifluoromethyl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C(F)(F)F)C(C=1)=CC=CC=1C=1N=CON=1 CXGGFUAERWUYLI-GOSISDBHSA-N 0.000 claims description 3
• APWITTXYMQNNTN-LJQANCHMSA-N [(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)-4-(trifluoromethyl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C(F)(F)F)C(C=1)=CC=CC=1N1N=CC=N1 APWITTXYMQNNTN-LJQANCHMSA-N 0.000 claims description 3
• RFRBKJBYJXZXKQ-LJQANCHMSA-N [(3r)-3-[[4-methyl-3-(1,3-thiazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2SC=CN=2)C)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 RFRBKJBYJXZXKQ-LJQANCHMSA-N 0.000 claims description 3
• XOKDIMBLNFVNEH-HXUWFJFHSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C(=C1N1N=CC=N1)C)C)C(C(=CC=1)F)=CC=1N1N=CC=N1 XOKDIMBLNFVNEH-HXUWFJFHSA-N 0.000 claims description 3
• NERGNQKZFUFHEN-HXUWFJFHSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=CC=C(C=1N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 NERGNQKZFUFHEN-HXUWFJFHSA-N 0.000 claims description 3
• QCNZPQHXWUCBEP-LJQANCHMSA-N [4-fluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)F)C(C=1)=CC=CC=1N1N=CC=N1 QCNZPQHXWUCBEP-LJQANCHMSA-N 0.000 claims description 3
• 239000004480 active ingredient Substances 0.000 claims description 3
• GJMZHSIKGICIAT-RPMZFOOHSA-N C[C@@H]1CN([C@@H](CO1)CC1=CC(=CC=C1)C1=NC=CC=N1)C=1C(=C(C=CC1)C(=O)C1=C(C(=CC=C1)N1C[C@H](OC[C@H]1CC1=CC(=CC=C1)C1=NC=CC=N1)C)N1N=CC=N1)N1N=CC=N1 Chemical compound C[C@@H]1CN([C@@H](CO1)CC1=CC(=CC=C1)C1=NC=CC=N1)C=1C(=C(C=CC1)C(=O)C1=C(C(=CC=C1)N1C[C@H](OC[C@H]1CC1=CC(=CC=C1)C1=NC=CC=N1)C)N1N=CC=N1)N1N=CC=N1 GJMZHSIKGICIAT-RPMZFOOHSA-N 0.000 claims description 2
• UJDZZHFYTLBQSA-FGZHOGPDSA-N [(2R,5R)-2-ethyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C(C)[C@@H]1CN([C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1)C(=O)C1=C(C=C(C=C1)C)N1N=CC=N1 UJDZZHFYTLBQSA-FGZHOGPDSA-N 0.000 claims description 2
• ACKAOVNXPNOWIE-DENIHFKCSA-N [(2R,5R)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C[C@@H]1CN([C@H](Cc2cccc(c2)-c2ncccn2)CO1)C(=O)c1cc(C)ccc1-n1nccn1 ACKAOVNXPNOWIE-DENIHFKCSA-N 0.000 claims description 2
• OSHBRXGINANDJA-YLJYHZDGSA-N [(2R,5R)-5-[[2-fluoro-5-(triazol-1-yl)phenyl]methyl]-2-methylmorpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C(=O)C2=C(C=CC(=C2)C)N2N=CC=N2)C)C=C(C=C1)N1N=NC=C1 OSHBRXGINANDJA-YLJYHZDGSA-N 0.000 claims description 2
• MRMSRUZHMOGZGF-YLJYHZDGSA-N [(2R,5R)-5-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]-2-methylmorpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C(=O)C2=C(C=C(C=C2)C)N2N=CC=N2)C)C=C(C=C1)N1N=CC=N1 MRMSRUZHMOGZGF-YLJYHZDGSA-N 0.000 claims description 2
• CWXMVKZSRVPZAO-YLJYHZDGSA-N [(2r,5r)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 CWXMVKZSRVPZAO-YLJYHZDGSA-N 0.000 claims description 2
• BLNLRXMYYDRXJH-YLJYHZDGSA-N [(2r,5r)-5-[[2-fluoro-5-(triazol-1-yl)phenyl]methyl]-2-methylmorpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1N1C=CN=N1 BLNLRXMYYDRXJH-YLJYHZDGSA-N 0.000 claims description 2
• OBGUWOPMHXCGQJ-GOSISDBHSA-N [(3R)-3-[(4-hydroxy-3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound Oc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncccn1 OBGUWOPMHXCGQJ-GOSISDBHSA-N 0.000 claims description 2
• KJPCUIQPIJYTDA-HXUWFJFHSA-N [(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[3,4-dimethyl-2-(triazol-2-yl)phenyl]methanone Chemical compound Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(ccc2Cl)-n2nccn2)c(c1C)-n1nccn1 KJPCUIQPIJYTDA-HXUWFJFHSA-N 0.000 claims description 2
• PHEQMGRTEIENAJ-LJQANCHMSA-N [(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(ccc2Cl)-n2nccn2)c(c1)-n1nccn1 PHEQMGRTEIENAJ-LJQANCHMSA-N 0.000 claims description 2
• HYFRBSMLWUEXKY-GOSISDBHSA-N [(3R)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)-4-(trifluoromethyl)phenyl]methanone Chemical compound Fc1ccc(cc1C[C@@H]1COCCN1C(=O)c1ccc(cc1-n1nccn1)C(F)(F)F)-n1nccn1 HYFRBSMLWUEXKY-GOSISDBHSA-N 0.000 claims description 2
• JBGQDYPWYFNNTI-GOSISDBHSA-N [(3R)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound COc1ccc(c(c1)C(=O)N1CCOC[C@H]1Cc1cc(ccc1F)-n1nccn1)-n1nccn1 JBGQDYPWYFNNTI-GOSISDBHSA-N 0.000 claims description 2
• LUSDGIQGCBLNQS-HXUWFJFHSA-N [(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 LUSDGIQGCBLNQS-HXUWFJFHSA-N 0.000 claims description 2
• LZJVNRGGFLKPHX-JOCHJYFZSA-N [(3r)-3-[(2-methyl-5-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2C)N2N=CC=C2)OCCN1C(=O)C1=CC=CC(C)=C1N1N=CC=N1 LZJVNRGGFLKPHX-JOCHJYFZSA-N 0.000 claims description 2
• NSPDBKKKFMEMRB-HXUWFJFHSA-N [(3r)-3-[(3-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1C=CC=N1 NSPDBKKKFMEMRB-HXUWFJFHSA-N 0.000 claims description 2
• HZTIXYMNAITACJ-LJQANCHMSA-N [(3r)-3-[(4-methoxy-3-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)N2N=CC=C2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 HZTIXYMNAITACJ-LJQANCHMSA-N 0.000 claims description 2
• KKEOYRYRWVSPJZ-HXUWFJFHSA-N [(3r)-3-[(4-methoxy-3-pyridin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2N=CC=CC=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 KKEOYRYRWVSPJZ-HXUWFJFHSA-N 0.000 claims description 2
• OLMUIMIZDWOYII-OAQYLSRUSA-N [(3r)-3-[(4-methoxy-3-pyridin-3-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2C=NC=CC=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 OLMUIMIZDWOYII-OAQYLSRUSA-N 0.000 claims description 2
• OREIPZHDUFKPTP-LJQANCHMSA-N [(3r)-3-[(4-methoxy-3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2N=CC=CN=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 OREIPZHDUFKPTP-LJQANCHMSA-N 0.000 claims description 2
• WVPNFJYCRRGGLI-GOSISDBHSA-N [(3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C(=CC=1)F)=CC=1C=1N=CON=1 WVPNFJYCRRGGLI-GOSISDBHSA-N 0.000 claims description 2
• HVGUQKUDHLWJBC-GOSISDBHSA-N [(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)N2N=CC=N2)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 HVGUQKUDHLWJBC-GOSISDBHSA-N 0.000 claims description 2
• BUUBXHARNCJISZ-GOSISDBHSA-N [(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[4-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)OC)C(C(=CC=1)F)=CC=1N1N=CC=N1 BUUBXHARNCJISZ-GOSISDBHSA-N 0.000 claims description 2
• CSOMRAVZERRDSF-GOSISDBHSA-N [(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C=1N=CON=1 CSOMRAVZERRDSF-GOSISDBHSA-N 0.000 claims description 2
• KXYYELXHLGICGL-HXUWFJFHSA-N [(3r)-3-[[3-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=CC=C(C=1N1N=CC=N1)C)C(C=1)=CC(Cl)=CC=1N1N=CC=N1 KXYYELXHLGICGL-HXUWFJFHSA-N 0.000 claims description 2
• LHHCFJSPYOKYPR-HXUWFJFHSA-N [(3r)-3-[[3-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C=1)=CC(Cl)=CC=1N1N=CC=N1 LHHCFJSPYOKYPR-HXUWFJFHSA-N 0.000 claims description 2
• PNRIERFKCYVVOG-GOSISDBHSA-N [(3r)-3-[[4-methoxy-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C2=NOC=N2)OC)OCCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1 PNRIERFKCYVVOG-GOSISDBHSA-N 0.000 claims description 2
• GHEMSERNBZGDLL-GOSISDBHSA-N [(3r)-3-[[4-methoxy-3-(1,3-oxazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2OC=CN=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 GHEMSERNBZGDLL-GOSISDBHSA-N 0.000 claims description 2
• XLQIWSDYHVBNIH-LJQANCHMSA-N [(3r)-3-[[4-methyl-3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)N2N=CC=N2)C)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 XLQIWSDYHVBNIH-LJQANCHMSA-N 0.000 claims description 2
• HCNLIVZSGOZAEH-LJQANCHMSA-N [2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 HCNLIVZSGOZAEH-LJQANCHMSA-N 0.000 claims description 2
• AHOIUZFUVOTFMM-QGZVFWFLSA-N [2-fluoro-3-methoxy-6-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1F)OC)N1N=CC=N1)C(C(=CC=1)F)=CC=1N1N=CC=N1 AHOIUZFUVOTFMM-QGZVFWFLSA-N 0.000 claims description 2
• VVTLUCANNQJJLA-GOSISDBHSA-N [2-fluoro-3-methoxy-6-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1F)OC)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 VVTLUCANNQJJLA-GOSISDBHSA-N 0.000 claims description 2
• KTJOHPLNNYAVJM-HXUWFJFHSA-N [2-fluoro-3-methyl-6-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1F)C)N1N=CC=N1)C(C=1)=CC=CC=1N1C=CC=N1 KTJOHPLNNYAVJM-HXUWFJFHSA-N 0.000 claims description 2
• VPQUBVYYWSMYEA-HXUWFJFHSA-N [2-fluoro-3-methyl-6-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1F)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 VPQUBVYYWSMYEA-HXUWFJFHSA-N 0.000 claims description 2
• STZDRKWMTBHWJI-GOSISDBHSA-N [2-fluoro-3-methyl-6-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1F)C)N1N=CC=N1)C(C(=CC=1)F)=CC=1N1N=CC=N1 STZDRKWMTBHWJI-GOSISDBHSA-N 0.000 claims description 2
• JNZNQAZDCIXPAH-LJQANCHMSA-N [2-fluoro-3-methyl-6-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1F)C)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 JNZNQAZDCIXPAH-LJQANCHMSA-N 0.000 claims description 2
• IEHBRXSPEXUDES-AUSIDOKSSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=C(C)C(C)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 IEHBRXSPEXUDES-AUSIDOKSSA-N 0.000 claims description 2
• DFLPJQGANRAIIM-OAQYLSRUSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C(=C1N1N=CC=N1)C)C)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 DFLPJQGANRAIIM-OAQYLSRUSA-N 0.000 claims description 2
• YGTXKPMZPUBWGV-QGZVFWFLSA-N [3-chloro-2-(triazol-2-yl)phenyl]-[(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound Clc1ccc(cc1C[C@@H]1COCCN1C(=O)c1cccc(Cl)c1-n1nccn1)-n1nccn1 YGTXKPMZPUBWGV-QGZVFWFLSA-N 0.000 claims description 2
• IGNKAYVYFKMOBL-GOSISDBHSA-N [3-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=CC=C(C=1N1N=CC=N1)Cl)C(C=1)=CC=CC=1N1N=CC=N1 IGNKAYVYFKMOBL-GOSISDBHSA-N 0.000 claims description 2
• UFYCDZYJXMCYQI-GHTZIAJQSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(3s,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@@H](N1C(=O)C=1C(=C(C)C=CC=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 UFYCDZYJXMCYQI-GHTZIAJQSA-N 0.000 claims description 2
• HMSWWKWVPAKARQ-MRXNPFEDSA-N [4,5-difluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)F)F)C(C(=CC=1)F)=CC=1N1N=CC=N1 HMSWWKWVPAKARQ-MRXNPFEDSA-N 0.000 claims description 2
• KOVCCWGOMZVONL-MRXNPFEDSA-N [4,5-difluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)F)F)C(C=1)=CC=CC=1C=1N=CON=1 KOVCCWGOMZVONL-MRXNPFEDSA-N 0.000 claims description 2
• HJRBUDPCLJIXSQ-LJQANCHMSA-N [4,5-dimethoxy-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)OC)OC)C(C=1)=CC=CC=1N1N=CC=N1 HJRBUDPCLJIXSQ-LJQANCHMSA-N 0.000 claims description 2
• DPAIDVFQHYLKSX-HXUWFJFHSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)C)C)C(C(=CC=1)F)=CC=1N1N=CC=N1 DPAIDVFQHYLKSX-HXUWFJFHSA-N 0.000 claims description 2
• WWEKFLWFASRPJA-OAQYLSRUSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)C)C)C(C=1)=CC=CC=1N1N=CC=N1 WWEKFLWFASRPJA-OAQYLSRUSA-N 0.000 claims description 2
• QBNJEFPDYRBZMY-SIKLNZKXSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3s,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@@H](N1C(=O)C=1C(=CC(C)=C(C)C=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 QBNJEFPDYRBZMY-SIKLNZKXSA-N 0.000 claims description 2
• JOAYSRXNJHJJBL-DYESRHJHSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC(Cl)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 JOAYSRXNJHJJBL-DYESRHJHSA-N 0.000 claims description 2
• RYPOYEQLSNWXDC-DNVCBOLYSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-5-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]-2-methylmorpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC(Cl)=CC=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1N1N=CC=N1 RYPOYEQLSNWXDC-DNVCBOLYSA-N 0.000 claims description 2
• NNBZSPNSBCOMJO-LJQANCHMSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)C=2N=CC=CN=2)OCCN1C(=O)C1=CC=C(Cl)C=C1N1N=CC=N1 NNBZSPNSBCOMJO-LJQANCHMSA-N 0.000 claims description 2
• SBDNJLCIYJRHKZ-QGZVFWFLSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)C2=NOC=N2)OCCN1C(=O)C1=CC=C(Cl)C=C1N1N=CC=N1 SBDNJLCIYJRHKZ-QGZVFWFLSA-N 0.000 claims description 2
• IARRCNRCFRHKHB-GOSISDBHSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)N2N=CC=N2)OCCN1C(=O)C1=CC=C(Cl)C=C1N1N=CC=N1 IARRCNRCFRHKHB-GOSISDBHSA-N 0.000 claims description 2
• BZOBPULTAMYVQD-HXUWFJFHSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-methyl-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2C)N2N=CC=N2)OCCN1C(=O)C1=CC=C(Cl)C=C1N1N=CC=N1 BZOBPULTAMYVQD-HXUWFJFHSA-N 0.000 claims description 2
• JRGASLNNEVZZRN-QGZVFWFLSA-N [4-chloro-5-methoxy-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)Cl)OC)C(C(=CC=1)F)=CC=1N1N=CC=N1 JRGASLNNEVZZRN-QGZVFWFLSA-N 0.000 claims description 2
• XKKKABNXFDRANJ-GOSISDBHSA-N [4-chloro-5-methoxy-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)Cl)OC)C(C=1)=CC=CC=1N1N=CC=N1 XKKKABNXFDRANJ-GOSISDBHSA-N 0.000 claims description 2
• CZXWCWCRILWJKE-QGZVFWFLSA-N [4-fluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[4-methoxy-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C2=NOC=N2)OC)OCCN1C(=O)C1=CC=C(F)C=C1N1N=CC=N1 CZXWCWCRILWJKE-QGZVFWFLSA-N 0.000 claims description 2
• WOQOCTXBEIMJQF-XMSQKQJNSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(2r,3r)-2-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(CCO[C@@H]1C)C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 WOQOCTXBEIMJQF-XMSQKQJNSA-N 0.000 claims description 2
• WOQOCTXBEIMJQF-PGRDOPGGSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(2s,3r)-2-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(CCO[C@H]1C)C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 WOQOCTXBEIMJQF-PGRDOPGGSA-N 0.000 claims description 2
• QRQCKASOXSZLKU-OAQYLSRUSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3R)-3-[[2-methyl-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound CC1=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=C(C=C2)C)N2N=CC=N2)C=C(C=C1)N1N=CC=N1 QRQCKASOXSZLKU-OAQYLSRUSA-N 0.000 claims description 2
• FCVGUKJNRFNLDS-WIYYLYMNSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3r,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@H](N1C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 FCVGUKJNRFNLDS-WIYYLYMNSA-N 0.000 claims description 2
• FCVGUKJNRFNLDS-GHTZIAJQSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3s,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@@H](N1C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 FCVGUKJNRFNLDS-GHTZIAJQSA-N 0.000 claims description 2
• SMVHMTBUOLIQMT-OXQOHEQNSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC=C(Cl)C=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 SMVHMTBUOLIQMT-OXQOHEQNSA-N 0.000 claims description 2
• LAINVSFGRYRKDA-HXUWFJFHSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)Cl)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 LAINVSFGRYRKDA-HXUWFJFHSA-N 0.000 claims description 2
• RWRHTRNNYAAULR-GOSISDBHSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)N2N=CC=N2)OCCN1C(=O)C1=CC(Cl)=CC=C1N1N=CC=N1 RWRHTRNNYAAULR-GOSISDBHSA-N 0.000 claims description 2
• CWBKFZFKBHRMPJ-LJQANCHMSA-N [5-methoxy-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)OC)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 CWBKFZFKBHRMPJ-LJQANCHMSA-N 0.000 claims description 2
• DZMITGRLYMROFK-WZONZLPQSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(2r,3r)-2-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(CCO[C@@H]1C)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 DZMITGRLYMROFK-WZONZLPQSA-N 0.000 claims description 2
• WQKDFCTZXNZINF-OAQYLSRUSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrazin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=CN=CC=N1 WQKDFCTZXNZINF-OAQYLSRUSA-N 0.000 claims description 2
• KQPLEQHOKPZPHW-HSZRJFAPSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyridin-4-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=CC=NC=C1 KQPLEQHOKPZPHW-HSZRJFAPSA-N 0.000 claims description 2
• HBIJQRRDMMOOSE-JOCHJYFZSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrrol-1-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1C=CC=C1 HBIJQRRDMMOOSE-JOCHJYFZSA-N 0.000 claims description 2
• LZAJTUGFVUQFAB-LJQANCHMSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C=1N=CON=1 LZAJTUGFVUQFAB-LJQANCHMSA-N 0.000 claims description 2
• PUZJVVRRRYQHLK-HXUWFJFHSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-triazol-1-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1C=NC=N1 PUZJVVRRRYQHLK-HXUWFJFHSA-N 0.000 claims description 2
• JQRRTXWUYXPFEP-HXUWFJFHSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 JQRRTXWUYXPFEP-HXUWFJFHSA-N 0.000 claims description 2
• GZYDOWPTMSDVRI-HXUWFJFHSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[4-methyl-3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=C(C)C=1N1N=CC=N1 GZYDOWPTMSDVRI-HXUWFJFHSA-N 0.000 claims description 2
• ZITMXEDGKUYCKA-HXUWFJFHSA-N [6-methyl-3-(triazol-2-yl)pyridin-2-yl]-[(3r)-3-[(3-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(N=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1C=CC=N1 ZITMXEDGKUYCKA-HXUWFJFHSA-N 0.000 claims description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• DCMSTVVYTKCBDX-LJQANCHMSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C=1)=CC=CC=1C=1N=CON=1 DCMSTVVYTKCBDX-LJQANCHMSA-N 0.000 claims 2
• BVVSWRIBSPAQPU-HXUWFJFHSA-N 4-(triazol-2-yl)-3-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholine-4-carbonyl]benzonitrile Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C#N)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 BVVSWRIBSPAQPU-HXUWFJFHSA-N 0.000 claims 1
• SBZFLVKAWPYIDI-FGZHOGPDSA-N [(2R,5R)-2-ethyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C(C)[C@@H]1CN([C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1)C(=O)C1=C(C=CC(=C1)C)N1N=CC=N1 SBZFLVKAWPYIDI-FGZHOGPDSA-N 0.000 claims 1
• QOXZYZJSLRTDNB-YLJYHZDGSA-N [(2R,5R)-5-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]-2-methylmorpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C(=O)C2=C(C(=CC=C2)C)N2N=CC=N2)C)C=C(C=C1)N1N=CC=N1 QOXZYZJSLRTDNB-YLJYHZDGSA-N 0.000 claims 1
• IEJDUPAJXHWTNS-YLJYHZDGSA-N [(2R,5R)-5-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]-2-methylmorpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C(=O)C2=C(C=CC(=C2)C)N2N=CC=N2)C)C=C(C=C1)N1N=CC=N1 IEJDUPAJXHWTNS-YLJYHZDGSA-N 0.000 claims 1
• BAHLPIRZKQNNOE-GOSISDBHSA-N [(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound ClC1=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C(C=C1)N1N=CC=N1 BAHLPIRZKQNNOE-GOSISDBHSA-N 0.000 claims 1
• IKDFBCDOUXZRDH-LJQANCHMSA-N [(3R)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(ccc2F)-n2nccn2)c1-n1nccn1 IKDFBCDOUXZRDH-LJQANCHMSA-N 0.000 claims 1
• SKTHZCLPOHWFMH-HXUWFJFHSA-N [(3R)-3-[[2-methyl-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound CC1=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C(C=C1)N1N=CC=N1 SKTHZCLPOHWFMH-HXUWFJFHSA-N 0.000 claims 1
• KJXCOZMMUXZQGE-GOSISDBHSA-N [(3R)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)-3-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)c1cccc(C(=O)N2CCOC[C@H]2Cc2cccc(c2)-n2nccn2)c1-n1nccn1 KJXCOZMMUXZQGE-GOSISDBHSA-N 0.000 claims 1
• PNBXBOOTVNVZSH-LJQANCHMSA-N [(3R)-3-[[3-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound FC=1C=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C(C1)N1N=CC=N1 PNBXBOOTVNVZSH-LJQANCHMSA-N 0.000 claims 1
• ZVAZIIXJYBKGIK-JOCHJYFZSA-N [(3r)-3-[(2-methyl-5-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C(=CC=1)C)=CC=1N1C=CC=N1 ZVAZIIXJYBKGIK-JOCHJYFZSA-N 0.000 claims 1
• AKVDRUIVHSDXNM-GOSISDBHSA-N [(3r)-3-[(4-chloro-3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2N=CC=CN=2)Cl)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 AKVDRUIVHSDXNM-GOSISDBHSA-N 0.000 claims 1
• CZERAVZVKNLXOP-LJQANCHMSA-N [(3r)-3-[(4-methoxy-3-pyrazin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2N=CC=NC=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 CZERAVZVKNLXOP-LJQANCHMSA-N 0.000 claims 1
• FURKPFKLIIWSMR-LJQANCHMSA-N [(3r)-3-[(4-methoxy-3-pyridazin-3-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2N=NC=CC=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 FURKPFKLIIWSMR-LJQANCHMSA-N 0.000 claims 1
• FJYYNLJIKKPGEW-GOSISDBHSA-N [(3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C(=CC=1)F)=CC=1C=1N=CON=1 FJYYNLJIKKPGEW-GOSISDBHSA-N 0.000 claims 1
• FYEWZQAALXXWSM-LJQANCHMSA-N [(3r)-3-[[3-(1,3-thiazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CS1 FYEWZQAALXXWSM-LJQANCHMSA-N 0.000 claims 1
• OYWUQQROZYATHC-JOCHJYFZSA-N [(3r)-3-[[3-(4-methylpyrimidin-2-yl)phenyl]methyl]morpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC(C)=N1 OYWUQQROZYATHC-JOCHJYFZSA-N 0.000 claims 1
• UWCQHIQVETWOCJ-GOSISDBHSA-N [(3r)-3-[[4-methoxy-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]-[2-methyl-6-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C2=NOC=N2)OC)OCCN1C(=O)C1=C(C)C=CC=C1N1N=CC=N1 UWCQHIQVETWOCJ-GOSISDBHSA-N 0.000 claims 1
• MLWGTDLBQDBZDR-YLJYHZDGSA-N [(3r,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COC[C@H](N1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 MLWGTDLBQDBZDR-YLJYHZDGSA-N 0.000 claims 1
• WBUINJWSFUWINW-HXUWFJFHSA-N [3,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=C(C)C=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C=1N=CON=1 WBUINJWSFUWINW-HXUWFJFHSA-N 0.000 claims 1
• PYRHLDRQRCTVES-OAQYLSRUSA-N [3,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=C(C)C=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 PYRHLDRQRCTVES-OAQYLSRUSA-N 0.000 claims 1
• CJILJTGWIHZLDC-CRAIPNDOSA-N [3-chloro-2-(triazol-2-yl)phenyl]-[(2R,5R)-5-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]-2-methylmorpholin-4-yl]methanone Chemical compound ClC=1C(=C(C=CC1)C(=O)N1C[C@H](OC[C@H]1CC1=C(C=CC(=C1)N1N=CC=N1)F)C)N1N=CC=N1 CJILJTGWIHZLDC-CRAIPNDOSA-N 0.000 claims 1
• DUUOWDLWEJVCSI-VQIMIIECSA-N [3-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=C(Cl)C=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 DUUOWDLWEJVCSI-VQIMIIECSA-N 0.000 claims 1
• IVIQQEWOFAIBMX-QGZVFWFLSA-N [3-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)N2N=CC=N2)OCCN1C(=O)C1=CC=CC(Cl)=C1N1N=CC=N1 IVIQQEWOFAIBMX-QGZVFWFLSA-N 0.000 claims 1
• OQHUOGSZVADTEQ-OAQYLSRUSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(3R)-3-[[2-methyl-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound CC1=C(C[C@H]2N(CCOC2)C(=O)C2=C(C(=CC=C2)C)N2N=CC=N2)C=C(C=C1)N1N=CC=N1 OQHUOGSZVADTEQ-OAQYLSRUSA-N 0.000 claims 1
• UFYCDZYJXMCYQI-WIYYLYMNSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(3r,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@H](N1C(=O)C=1C(=C(C)C=CC=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 UFYCDZYJXMCYQI-WIYYLYMNSA-N 0.000 claims 1
• DTAVCGIFLPXIFF-QGZVFWFLSA-N [4,5-difluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)F)F)C(C=1)=CC=CC=1N1N=CC=N1 DTAVCGIFLPXIFF-QGZVFWFLSA-N 0.000 claims 1
• PUBPGWFEGLTPSV-LJQANCHMSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)C)C)C(C(=CC=1)F)=CC=1C=1N=CON=1 PUBPGWFEGLTPSV-LJQANCHMSA-N 0.000 claims 1
• DLTFUAAXCYAOLA-HXUWFJFHSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[4-methyl-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)C)C)C(C=1)=CC=C(C)C=1C=1N=CON=1 DLTFUAAXCYAOLA-HXUWFJFHSA-N 0.000 claims 1
• MRZOKJFVVJMJLC-LJQANCHMSA-N [4-methoxy-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)OC)C(C=1)=CC=CC=1N1N=CC=N1 MRZOKJFVVJMJLC-LJQANCHMSA-N 0.000 claims 1
• VZSCFYBYGCGNNT-DNVCBOLYSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-5-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]-2-methylmorpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC=C(Cl)C=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1N1N=CC=N1 VZSCFYBYGCGNNT-DNVCBOLYSA-N 0.000 claims 1
• IBFHVKISQVPMHU-GOSISDBHSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)Cl)N1N=CC=N1)C(C=1)=CC=CC=1C=1N=CON=1 IBFHVKISQVPMHU-GOSISDBHSA-N 0.000 claims 1
• SYLDJPVOGVSYAI-HXUWFJFHSA-N [5-fluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)F)N1N=CC=N1)C(C=1)=CC=CC=1N1C=CC=N1 SYLDJPVOGVSYAI-HXUWFJFHSA-N 0.000 claims 1
• TXOLBWQUYQXATH-HXUWFJFHSA-N [5-methoxy-4-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)C)OC)C(C=1)=CC=CC=1N1N=CC=N1 TXOLBWQUYQXATH-HXUWFJFHSA-N 0.000 claims 1
• DZMITGRLYMROFK-FDDCHVKYSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(2s,3r)-2-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(CCO[C@H]1C)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 DZMITGRLYMROFK-FDDCHVKYSA-N 0.000 claims 1
• SBTZFUJQUNEVMJ-HSZRJFAPSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyridin-3-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=CC=CN=C1 SBTZFUJQUNEVMJ-HSZRJFAPSA-N 0.000 claims 1
• SPVLNBKCMBRTPX-OAQYLSRUSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-thiophen-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=CC=CS1 SPVLNBKCMBRTPX-OAQYLSRUSA-N 0.000 claims 1
• ARAHFWCCUIXFBE-GHTZIAJQSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3s,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@@H](N1C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 ARAHFWCCUIXFBE-GHTZIAJQSA-N 0.000 claims 1
• HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 1
• 238000000034 method Methods 0.000 description 145
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 124
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 89
• 238000006243 chemical reaction Methods 0.000 description 66
• 239000000243 solution Substances 0.000 description 59
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 55
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 54
• 102000002512 Orexin Human genes 0.000 description 54
• 108060005714 orexin Proteins 0.000 description 54
• 235000019439 ethyl acetate Nutrition 0.000 description 45
• 239000011541 reaction mixture Substances 0.000 description 41
• 239000011734 sodium Substances 0.000 description 37
• 239000012043 crude product Substances 0.000 description 35
• 239000000203 mixture Substances 0.000 description 35
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
• 239000002904 solvent Substances 0.000 description 28
• 239000000543 intermediate Substances 0.000 description 27
• 239000000284 extract Substances 0.000 description 26
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
• 239000010410 layer Substances 0.000 description 22
• 239000000725 suspension Substances 0.000 description 22
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
• 230000015654 memory Effects 0.000 description 21
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
• 239000008346 aqueous phase Substances 0.000 description 20
• 210000004556 brain Anatomy 0.000 description 19
• 239000012267 brine Substances 0.000 description 19
• 238000002360 preparation method Methods 0.000 description 19
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
• 230000007958 sleep Effects 0.000 description 18
• 208000019116 sleep disease Diseases 0.000 description 17
• 239000007787 solid Substances 0.000 description 17
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
• 238000003818 flash chromatography Methods 0.000 description 15
• 230000035882 stress Effects 0.000 description 15
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 14
• UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 14
• 239000003480 eluent Substances 0.000 description 14
• 238000007429 general method Methods 0.000 description 14
• 206010022437 insomnia Diseases 0.000 description 14
• 238000000746 purification Methods 0.000 description 14
• 102000005962 receptors Human genes 0.000 description 13
• 108020003175 receptors Proteins 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 12
• 239000002585 base Substances 0.000 description 12
• 229910052796 boron Inorganic materials 0.000 description 12
• 208000035475 disorder Diseases 0.000 description 12
• 239000011737 fluorine Substances 0.000 description 12
• 229910052731 fluorine Inorganic materials 0.000 description 12
• 229910052786 argon Inorganic materials 0.000 description 11
• 239000002253 acid Substances 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 230000004064 dysfunction Effects 0.000 description 10
• 239000012074 organic phase Substances 0.000 description 10
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
• 238000002953 preparative HPLC Methods 0.000 description 10
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• 210000004027 cell Anatomy 0.000 description 9
• 208000010877 cognitive disease Diseases 0.000 description 9
• 230000000694 effects Effects 0.000 description 9
• 229920006395 saturated elastomer Polymers 0.000 description 9
• LSXCLMMIDIVSFG-UHFFFAOYSA-N 3-benzylmorpholine Chemical compound C=1C=CC=CC=1CC1COCCN1 LSXCLMMIDIVSFG-UHFFFAOYSA-N 0.000 description 8
• 241000700159 Rattus Species 0.000 description 8
• 125000003545 alkoxy group Chemical group 0.000 description 8
• 230000003542 behavioural effect Effects 0.000 description 8
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 208000028173 post-traumatic stress disease Diseases 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
• BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 7
• 229940123730 Orexin receptor antagonist Drugs 0.000 description 7
• 150000001412 amines Chemical class 0.000 description 7
• 229910000085 borane Inorganic materials 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 238000001514 detection method Methods 0.000 description 7
• 150000002148 esters Chemical class 0.000 description 7
• 230000013016 learning Effects 0.000 description 7
• 229910052751 metal Inorganic materials 0.000 description 7
• 239000002184 metal Substances 0.000 description 7
• VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 7
• 229910052763 palladium Inorganic materials 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• OBBREAYWJPJKLV-SNVBAGLBSA-N (5R)-5-[(3-iodophenyl)methyl]morpholin-3-one Chemical compound Ic1cccc(C[C@@H]2COCC(=O)N2)c1 OBBREAYWJPJKLV-SNVBAGLBSA-N 0.000 description 6
• 208000024827 Alzheimer disease Diseases 0.000 description 6
• 208000027534 Emotional disease Diseases 0.000 description 6
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
• 208000008589 Obesity Diseases 0.000 description 6
• 238000006069 Suzuki reaction reaction Methods 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 230000036528 appetite Effects 0.000 description 6
• 235000019789 appetite Nutrition 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 6
• 238000010828 elution Methods 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 6
• DAQSBVNCJRPPAZ-MRVPVSSYSA-N (2r)-2-amino-3-(5-bromo-2-fluorophenyl)propan-1-ol Chemical compound OC[C@H](N)CC1=CC(Br)=CC=C1F DAQSBVNCJRPPAZ-MRVPVSSYSA-N 0.000 description 5
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 5
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
• 208000030814 Eating disease Diseases 0.000 description 5
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
• 239000012317 TBTU Substances 0.000 description 5
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 5
• 230000036626 alertness Effects 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 230000006399 behavior Effects 0.000 description 5
• 239000003054 catalyst Substances 0.000 description 5
• 229910052802 copper Inorganic materials 0.000 description 5
• 239000010949 copper Substances 0.000 description 5
• 230000008878 coupling Effects 0.000 description 5
• 238000010168 coupling process Methods 0.000 description 5
• 238000005859 coupling reaction Methods 0.000 description 5
• 230000003001 depressive effect Effects 0.000 description 5
• 235000014632 disordered eating Nutrition 0.000 description 5
• 230000002996 emotional effect Effects 0.000 description 5
• 230000007613 environmental effect Effects 0.000 description 5
• 230000007787 long-term memory Effects 0.000 description 5
• 230000004630 mental health Effects 0.000 description 5
• 235000020824 obesity Nutrition 0.000 description 5
• XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 5
• 229960004448 pentamidine Drugs 0.000 description 5
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 5
• 239000011550 stock solution Substances 0.000 description 5
• 230000002194 synthesizing effect Effects 0.000 description 5
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
• WNUFHOFTRCYWQA-LLVKDONJSA-N (3R)-3-[(3-iodophenyl)methyl]morpholine Chemical compound Ic1cccc(C[C@@H]2COCCN2)c1 WNUFHOFTRCYWQA-LLVKDONJSA-N 0.000 description 4
• WDQHADONQHFXGP-SECBINFHSA-N (5R)-5-[(3-iodo-4-methoxyphenyl)methyl]morpholin-3-one Chemical compound COc1ccc(C[C@@H]2COCC(=O)N2)cc1I WDQHADONQHFXGP-SECBINFHSA-N 0.000 description 4
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 4
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 4
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 4
• FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 4
• SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 description 4
• YSSWCSYAQLKZNM-UHFFFAOYSA-N 2-(bromomethyl)-1-fluoro-4-iodobenzene Chemical compound FC1=CC=C(I)C=C1CBr YSSWCSYAQLKZNM-UHFFFAOYSA-N 0.000 description 4
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
• LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 4
• 208000020925 Bipolar disease Diseases 0.000 description 4
• 208000032841 Bulimia Diseases 0.000 description 4
• 206010006550 Bulimia nervosa Diseases 0.000 description 4
• 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 4
• 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 4
• 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 4
• 208000020401 Depressive disease Diseases 0.000 description 4
• 208000011688 Generalised anxiety disease Diseases 0.000 description 4
• 206010026749 Mania Diseases 0.000 description 4
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 4
• 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
• 230000002378 acidificating effect Effects 0.000 description 4
• 229940025084 amphetamine Drugs 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• 230000037007 arousal Effects 0.000 description 4
• 150000001502 aryl halides Chemical class 0.000 description 4
• 238000006254 arylation reaction Methods 0.000 description 4
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 4
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
• 208000014679 binge eating disease Diseases 0.000 description 4
• 229940098773 bovine serum albumin Drugs 0.000 description 4
• 229910052794 bromium Inorganic materials 0.000 description 4
• 229960003920 cocaine Drugs 0.000 description 4
• 230000007547 defect Effects 0.000 description 4
• 238000010511 deprotection reaction Methods 0.000 description 4
• OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 4
• 235000013305 food Nutrition 0.000 description 4
• 235000012631 food intake Nutrition 0.000 description 4
• 235000019253 formic acid Nutrition 0.000 description 4
• 208000029364 generalized anxiety disease Diseases 0.000 description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 238000004949 mass spectrometry Methods 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 229960002715 nicotine Drugs 0.000 description 4
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
• OFNHNCAUVYOTPM-IIIOAANCSA-N orexin-a Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N2)[C@@H](C)O)=O)CSSC1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CNC=N1 OFNHNCAUVYOTPM-IIIOAANCSA-N 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
• 208000020016 psychiatric disease Diseases 0.000 description 4
• 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 229910000104 sodium hydride Inorganic materials 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 208000011117 substance-related disease Diseases 0.000 description 4
• 208000011580 syndromic disease Diseases 0.000 description 4
• PSCAGVVDAZMIMQ-GFCCVEGCSA-N tert-butyl N-[(2R)-1-hydroxy-3-(3-iodophenyl)propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)Cc1cccc(I)c1 PSCAGVVDAZMIMQ-GFCCVEGCSA-N 0.000 description 4
• PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
• 239000003039 volatile agent Substances 0.000 description 4
• 239000003643 water by type Substances 0.000 description 4
• RNOKFZIPFZZIAU-UHFFFAOYSA-N (2-fluoro-5-iodophenyl)methanol Chemical compound OCC1=CC(I)=CC=C1F RNOKFZIPFZZIAU-UHFFFAOYSA-N 0.000 description 3
• NMQFFSLJUVKVNT-ZOWNYOTGSA-N (2s)-2-[[3-(triazol-2-yl)phenyl]methyl]piperidine;hydrochloride Chemical compound Cl.C=1C=CC(N2N=CC=N2)=CC=1C[C@@H]1CCCCN1 NMQFFSLJUVKVNT-ZOWNYOTGSA-N 0.000 description 3
• BKGWUIPRQDBKPY-SNVBAGLBSA-N (5R)-5-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound COc1ccc(C[C@@H]2COCC(=O)N2)cc1 BKGWUIPRQDBKPY-SNVBAGLBSA-N 0.000 description 3
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
• QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 3
• UTENUPFWBIFKPW-UHFFFAOYSA-N 2-(triazol-2-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1N=CC=N1 UTENUPFWBIFKPW-UHFFFAOYSA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 3
• AGKWQJDGILALHN-UHFFFAOYSA-N 2-chloro-N-[1-hydroxy-3-(3-iodophenyl)-2-methylpropan-2-yl]acetamide Chemical compound ClCC(=O)NC(CC1=CC(=CC=C1)I)(C)CO AGKWQJDGILALHN-UHFFFAOYSA-N 0.000 description 3
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• OQNSCJJJJMVDNE-CYBMUJFWSA-N C(C)(C)(C)OC(N[C@H](CC1=CC(=CC=C1)I)C(=O)C)=O Chemical compound C(C)(C)(C)OC(N[C@H](CC1=CC(=CC=C1)I)C(=O)C)=O OQNSCJJJJMVDNE-CYBMUJFWSA-N 0.000 description 3
• VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 3
• 239000007821 HATU Substances 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 239000012981 Hank's balanced salt solution Substances 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
• 229930182821 L-proline Natural products 0.000 description 3
• 201000002832 Lewy body dementia Diseases 0.000 description 3
• 108050000742 Orexin Receptor Proteins 0.000 description 3
• 102000008834 Orexin receptor Human genes 0.000 description 3
• 206010062519 Poor quality sleep Diseases 0.000 description 3
• 206010070834 Sensitisation Diseases 0.000 description 3
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 230000029936 alkylation Effects 0.000 description 3
• 238000005804 alkylation reaction Methods 0.000 description 3
• 150000001414 amino alcohols Chemical class 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 235000019445 benzyl alcohol Nutrition 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 3
• 239000012230 colorless oil Substances 0.000 description 3
• 230000001276 controlling effect Effects 0.000 description 3
• OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• WEOSHBZRDUVWAK-UHFFFAOYSA-N diethyl 2-[(2-fluoro-5-iodophenyl)methyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanedioate Chemical compound CC(C)(C)OC(=O)NC(C(=O)OCC)(C(=O)OCC)CC1=CC(I)=CC=C1F WEOSHBZRDUVWAK-UHFFFAOYSA-N 0.000 description 3
• SJTBTXPLPLGEJF-UHFFFAOYSA-N ethyl 2-amino-3-(3-iodophenyl)-2-methylpropanoate Chemical compound CCOC(=O)C(C)(N)CC1=CC=CC(I)=C1 SJTBTXPLPLGEJF-UHFFFAOYSA-N 0.000 description 3
• 230000037406 food intake Effects 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000005056 memory consolidation Effects 0.000 description 3
• 230000036651 mood Effects 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 3
• IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 229960002429 proline Drugs 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 230000008313 sensitization Effects 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 239000012312 sodium hydride Substances 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• NMYODLKTGUEPAQ-CQSZACIVSA-N tert-butyl (3R)-3-[(3-iodophenyl)methyl]morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOC[C@H]1Cc1cccc(I)c1 NMYODLKTGUEPAQ-CQSZACIVSA-N 0.000 description 3
• RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
• 229910052725 zinc Inorganic materials 0.000 description 3
• 239000011701 zinc Substances 0.000 description 3
• OBSJNTGOXQHQRF-SECBINFHSA-N (2R)-2-amino-3-(3-iodophenyl)propan-1-ol Chemical compound N[C@@H](CO)Cc1cccc(I)c1 OBSJNTGOXQHQRF-SECBINFHSA-N 0.000 description 2
• GBINHMYGYUPSTD-BXUZGUMPSA-N (2R,3R)-2-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C[C@@H]1[C@H](NCCO1)CC1=CC(=CC=C1)N1N=CC=N1 GBINHMYGYUPSTD-BXUZGUMPSA-N 0.000 description 2
• FPSWQQMPSWZLDR-UKRRQHHQSA-N (2R,5R)-2-ethyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C(C)[C@@H]1CN[C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1 FPSWQQMPSWZLDR-UKRRQHHQSA-N 0.000 description 2
• VCAFOIGCMDSJPQ-ZYHUDNBSSA-N (2R,5R)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound C[C@@H]1C(N[C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1)=O VCAFOIGCMDSJPQ-ZYHUDNBSSA-N 0.000 description 2
• KDCNSORPXSBMLO-DGCLKSJQSA-N (2R,5R)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C[C@@H]1CN[C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1 KDCNSORPXSBMLO-DGCLKSJQSA-N 0.000 description 2
• PNHSUFMWROINQD-GBWFEORMSA-N (2R,5R)-5-[(2-fluoro-5-pyridazin-3-ylphenyl)methyl]-2-methylmorpholine hydrochloride Chemical compound Cl.FC1=C(C[C@@H]2CO[C@@H](CN2)C)C=C(C=C1)C=1N=NC=CC1 PNHSUFMWROINQD-GBWFEORMSA-N 0.000 description 2
• RXWZYWHULZPLGO-GBWFEORMSA-N (2R,5R)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholine hydrochloride Chemical compound Cl.FC1=C(C[C@@H]2CO[C@@H](CN2)C)C=C(C=C1)C1=NC=CC=N1 RXWZYWHULZPLGO-GBWFEORMSA-N 0.000 description 2
• QBWWNUOOWQYTNK-LDYMZIIASA-N (2R,5R)-5-[(3-iodophenyl)methyl]-2-methylmorpholin-3-one Chemical compound IC=1C=C(C[C@@H]2CO[C@@H](C(N2)=O)C)C=CC1 QBWWNUOOWQYTNK-LDYMZIIASA-N 0.000 description 2
• PXUCZFWUGIYYMY-ZYHUDNBSSA-N (2R,5R)-5-[[2-fluoro-5-(triazol-1-yl)phenyl]methyl]-2-methylmorpholine Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2)C)C=C(C=C1)N1N=NC=C1 PXUCZFWUGIYYMY-ZYHUDNBSSA-N 0.000 description 2
• CRXYATAKVBIIQM-ZYHUDNBSSA-N (2R,5R)-5-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]-2-methylmorpholine Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2)C)C=C(C=C1)N1N=CC=N1 CRXYATAKVBIIQM-ZYHUDNBSSA-N 0.000 description 2
• OZWXMJSNSVONMA-GZMMTYOYSA-N (2S)-2-chloro-N-[(2R)-1-hydroxy-3-(3-iodophenyl)propan-2-yl]propanamide Chemical compound IC=1C=C(C[C@H](CO)NC([C@H](C)Cl)=O)C=CC1 OZWXMJSNSVONMA-GZMMTYOYSA-N 0.000 description 2
• GBINHMYGYUPSTD-SMDDNHRTSA-N (2S,3R)-2-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C[C@H]1[C@H](NCCO1)CC1=CC(=CC=C1)N1N=CC=N1 GBINHMYGYUPSTD-SMDDNHRTSA-N 0.000 description 2
• VCAFOIGCMDSJPQ-CMPLNLGQSA-N (2S,5R)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound C[C@H]1C(N[C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1)=O VCAFOIGCMDSJPQ-CMPLNLGQSA-N 0.000 description 2
• KDCNSORPXSBMLO-WCQYABFASA-N (2S,5R)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C[C@H]1CN[C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1 KDCNSORPXSBMLO-WCQYABFASA-N 0.000 description 2
• FMJRAEYLUBSWEY-DDWIOCJRSA-N (2r)-2-amino-3-(3-iodophenyl)propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@H](N)CC1=CC=CC(I)=C1 FMJRAEYLUBSWEY-DDWIOCJRSA-N 0.000 description 2
• GVLHBFBFUSPHJO-SECBINFHSA-N (2r)-2-amino-3-(4-methoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(C[C@@H](N)CO)C=C1 GVLHBFBFUSPHJO-SECBINFHSA-N 0.000 description 2
• MPTBEGFNTNOLNZ-LLVKDONJSA-N (2r)-3-(3-iodophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC1=CC=CC(I)=C1 MPTBEGFNTNOLNZ-LLVKDONJSA-N 0.000 description 2
• BJTWKCPVKGFTJA-XRZFDKQNSA-N (2r,5r)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholine;hydrochloride Chemical compound Cl.C1O[C@H](C)CN[C@@H]1CC1=CC=CC(C=2N=CC=CN=2)=C1 BJTWKCPVKGFTJA-XRZFDKQNSA-N 0.000 description 2
• HUOYGRNYKOUAFE-QMMMGPOBSA-N (2s)-2-(iodoamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](NI)CC1=CC=CC=C1 HUOYGRNYKOUAFE-QMMMGPOBSA-N 0.000 description 2
• DWUNPDNAGCEMMX-LBPRGKRZSA-N (2s)-2-[(3-iodophenyl)methyl]piperidine Chemical compound IC1=CC=CC(C[C@H]2NCCCC2)=C1 DWUNPDNAGCEMMX-LBPRGKRZSA-N 0.000 description 2
• ORTYUBGXIIIBLA-NSHDSACASA-N (2s)-2-[(3-iodophenyl)methyl]pyrrolidine Chemical compound IC1=CC=CC(C[C@H]2NCCC2)=C1 ORTYUBGXIIIBLA-NSHDSACASA-N 0.000 description 2
• OBSJNTGOXQHQRF-VIFPVBQESA-N (2s)-2-amino-3-(3-iodophenyl)propan-1-ol Chemical compound OC[C@@H](N)CC1=CC=CC(I)=C1 OBSJNTGOXQHQRF-VIFPVBQESA-N 0.000 description 2
• FMJRAEYLUBSWEY-QRPNPIFTSA-N (2s)-2-amino-3-(3-iodophenyl)propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=CC(I)=C1 FMJRAEYLUBSWEY-QRPNPIFTSA-N 0.000 description 2
• LPQFBTXUYYZFFE-BTQNPOSSSA-N (3R)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholine hydrochloride Chemical compound Cl.FC1=C(C[C@H]2NCCOC2)C=C(C=C1)C1=NC=CC=N1 LPQFBTXUYYZFFE-BTQNPOSSSA-N 0.000 description 2
• VEPVTYYJXDBEML-CYBMUJFWSA-N (3R)-3-[(3-pyrazol-1-ylphenyl)methyl]morpholine Chemical compound N1(N=CC=C1)C=1C=C(C[C@H]2NCCOC2)C=CC1 VEPVTYYJXDBEML-CYBMUJFWSA-N 0.000 description 2
• YMKJMDYWOLXDAL-CQSZACIVSA-N (3R)-3-[(3-pyrrol-1-ylphenyl)methyl]morpholine Chemical compound N1(C=CC=C1)C=1C=C(C[C@H]2NCCOC2)C=CC1 YMKJMDYWOLXDAL-CQSZACIVSA-N 0.000 description 2
• MQFACFCCESWLPF-CYBMUJFWSA-N (3R)-3-[(4-methoxy-3-pyrazol-1-ylphenyl)methyl]morpholine Chemical compound COC1=C(C=C(C[C@H]2NCCOC2)C=C1)N1N=CC=C1 MQFACFCCESWLPF-CYBMUJFWSA-N 0.000 description 2
• GUEULQXXZJJPGH-LLVKDONJSA-N (3R)-3-[(4-methoxyphenyl)methyl]morpholine Chemical compound COC1=CC=C(C[C@H]2NCCOC2)C=C1 GUEULQXXZJJPGH-LLVKDONJSA-N 0.000 description 2
• QPBOIWWCOGQZTE-UTONKHPSSA-N (3R)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine hydrochloride Chemical compound Cl.O1N=C(N=C1)C=1C=C(C[C@H]2NCCOC2)C=CC1 QPBOIWWCOGQZTE-UTONKHPSSA-N 0.000 description 2
• UNMBVMNZQKTVKW-GFCCVEGCSA-N (3R)-3-[[3-(1,2,4-triazol-1-yl)phenyl]methyl]morpholine Chemical compound N1(N=CN=C1)C=1C=C(C[C@H]2NCCOC2)C=CC1 UNMBVMNZQKTVKW-GFCCVEGCSA-N 0.000 description 2
• ITFRPORPSQTINB-GFCCVEGCSA-N (3R)-3-[[3-(triazol-1-yl)phenyl]methyl]morpholine Chemical compound N1(N=NC=C1)C=1C=C(C[C@H]2NCCOC2)C=CC1 ITFRPORPSQTINB-GFCCVEGCSA-N 0.000 description 2
• NWHWYMIXXIXEKN-GFCCVEGCSA-N (3R)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound N=1N(N=CC1)C=1C=C(C[C@H]2NCCOC2)C=CC1 NWHWYMIXXIXEKN-GFCCVEGCSA-N 0.000 description 2
• GDXQYBYOCGKOQW-DGCLKSJQSA-N (3R,5R)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C[C@H]1N[C@@H](COC1)CC1=CC(=CC=C1)N1N=CC=N1 GDXQYBYOCGKOQW-DGCLKSJQSA-N 0.000 description 2
• GDXQYBYOCGKOQW-WCQYABFASA-N (3S,5R)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C[C@@H]1N[C@@H](COC1)CC1=CC(=CC=C1)N1N=CC=N1 GDXQYBYOCGKOQW-WCQYABFASA-N 0.000 description 2
• LQKSBIQGKSMREW-BTQNPOSSSA-N (3r)-3-[(2-fluoro-5-pyridazin-3-ylphenyl)methyl]morpholine;hydrochloride Chemical compound Cl.FC1=CC=C(C=2N=NC=CC=2)C=C1C[C@@H]1COCCN1 LQKSBIQGKSMREW-BTQNPOSSSA-N 0.000 description 2
• QRGQHRZLDVKJMS-CQSZACIVSA-N (3r)-3-[(2-methyl-5-pyrazol-1-ylphenyl)methyl]morpholine Chemical compound CC1=CC=C(N2N=CC=C2)C=C1C[C@@H]1COCCN1 QRGQHRZLDVKJMS-CQSZACIVSA-N 0.000 description 2
• XKVRIDLYXOFQPT-SNVBAGLBSA-N (3r)-3-[(3-iodo-4-methoxyphenyl)methyl]morpholine Chemical compound C1=C(I)C(OC)=CC=C1C[C@H]1NCCOC1 XKVRIDLYXOFQPT-SNVBAGLBSA-N 0.000 description 2
• DLSXYTDCIWMJGX-RFVHGSKJSA-N (3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine;hydrochloride Chemical compound Cl.FC1=CC=C(C2=NOC=N2)C=C1C[C@@H]1COCCN1 DLSXYTDCIWMJGX-RFVHGSKJSA-N 0.000 description 2
• LKGSUFULHOJHOS-RFVHGSKJSA-N (3r)-3-[[4-methoxy-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine;hydrochloride Chemical compound Cl.C1=C(C2=NOC=N2)C(OC)=CC=C1C[C@@H]1COCCN1 LKGSUFULHOJHOS-RFVHGSKJSA-N 0.000 description 2
• NWHWYMIXXIXEKN-LBPRGKRZSA-N (3s)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C=1C=CC(N2N=CC=N2)=CC=1C[C@H]1COCCN1 NWHWYMIXXIXEKN-LBPRGKRZSA-N 0.000 description 2
• LJOTZPHEEZQVMQ-CYBMUJFWSA-N (5R)-5-[(2-methyl-5-pyrazol-1-ylphenyl)methyl]morpholin-3-one Chemical compound CC1=C(C[C@@H]2COCC(N2)=O)C=C(C=C1)N1N=CC=C1 LJOTZPHEEZQVMQ-CYBMUJFWSA-N 0.000 description 2
• NEMGRSGEAMFLRV-GFCCVEGCSA-N (5R)-5-[(3-pyrazol-1-ylphenyl)methyl]morpholin-3-one Chemical compound O=C1COC[C@@H](Cc2cccc(c2)-n2cccn2)N1 NEMGRSGEAMFLRV-GFCCVEGCSA-N 0.000 description 2
• WCXVRKZHEBZRAM-CYBMUJFWSA-N (5R)-5-[(3-pyrrol-1-ylphenyl)methyl]morpholin-3-one Chemical compound N1(C=CC=C1)C=1C=C(C[C@@H]2COCC(N2)=O)C=CC1 WCXVRKZHEBZRAM-CYBMUJFWSA-N 0.000 description 2
• NQACIJHRJOLDFZ-GFCCVEGCSA-N (5R)-5-[(4-methoxy-3-pyrazol-1-ylphenyl)methyl]morpholin-3-one Chemical compound COC1=C(C=C(C[C@@H]2COCC(N2)=O)C=C1)N1N=CC=C1 NQACIJHRJOLDFZ-GFCCVEGCSA-N 0.000 description 2
• GVZWZOWAVZFUOC-LLVKDONJSA-N (5R)-5-[[3-(1,2,4-triazol-1-yl)phenyl]methyl]morpholin-3-one Chemical compound N1(N=CN=C1)C=1C=C(C[C@@H]2COCC(N2)=O)C=CC1 GVZWZOWAVZFUOC-LLVKDONJSA-N 0.000 description 2
• URKDLMUEFQSTGX-LLVKDONJSA-N (5R)-5-[[3-(triazol-1-yl)phenyl]methyl]morpholin-3-one Chemical compound N1(N=NC=C1)C=1C=C(C[C@@H]2COCC(N2)=O)C=CC1 URKDLMUEFQSTGX-LLVKDONJSA-N 0.000 description 2
• QRSUCLRXIYIEMG-LLVKDONJSA-N (5R)-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound O=C1COC[C@@H](Cc2cccc(c2)-n2nccn2)N1 QRSUCLRXIYIEMG-LLVKDONJSA-N 0.000 description 2
• LIKPAVQDIRETPJ-LDYMZIIASA-N (5R,6R)-5-[(3-iodophenyl)methyl]-6-methylmorpholin-3-one Chemical compound IC=1C=C(C[C@@H]2[C@H](OCC(N2)=O)C)C=CC1 LIKPAVQDIRETPJ-LDYMZIIASA-N 0.000 description 2
• OBBREAYWJPJKLV-JTQLQIEISA-N (5s)-5-[(3-iodophenyl)methyl]morpholin-3-one Chemical compound IC1=CC=CC(C[C@@H]2NC(=O)COC2)=C1 OBBREAYWJPJKLV-JTQLQIEISA-N 0.000 description 2
• QRSUCLRXIYIEMG-NSHDSACASA-N (5s)-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound N1C(=O)COC[C@@H]1CC1=CC=CC(N2N=CC=N2)=C1 QRSUCLRXIYIEMG-NSHDSACASA-N 0.000 description 2
• SFPQFQUXAJOWNF-UHFFFAOYSA-N 1,3-diiodobenzene Chemical compound IC1=CC=CC(I)=C1 SFPQFQUXAJOWNF-UHFFFAOYSA-N 0.000 description 2
• IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 2
• JHFAEUICJHBVHB-UHFFFAOYSA-N 1h-indol-2-ol Chemical compound C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 description 2
• JSQVAYFVQPDRES-UHFFFAOYSA-N 2-(triazol-2-yl)-3-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1N1N=CC=N1 JSQVAYFVQPDRES-UHFFFAOYSA-N 0.000 description 2
• XPIYCJXPRMNVBU-UHFFFAOYSA-N 2-amino-3-(3-iodophenyl)-2-methylpropan-1-ol Chemical compound OCC(N)(C)CC1=CC=CC(I)=C1 XPIYCJXPRMNVBU-UHFFFAOYSA-N 0.000 description 2
• BNWIEYDZOIMYMJ-SNVBAGLBSA-N 2-chloro-N-[(2R)-1-hydroxy-3-(3-iodophenyl)propan-2-yl]acetamide Chemical compound ClCC(=O)N[C@H](CC1=CC(=CC=C1)I)CO BNWIEYDZOIMYMJ-SNVBAGLBSA-N 0.000 description 2
• HNZPWRMQSCEGCM-SNVBAGLBSA-N 2-chloro-N-[(2R)-1-hydroxy-3-(4-methoxyphenyl)propan-2-yl]acetamide Chemical compound ClCC(=O)N[C@H](CC1=CC=C(C=C1)OC)CO HNZPWRMQSCEGCM-SNVBAGLBSA-N 0.000 description 2
• ARNFNRFSPMXZAG-LDYMZIIASA-N 2-chloro-N-[(2R,3R)-3-hydroxy-1-(3-iodophenyl)butan-2-yl]acetamide Chemical compound C[C@@H](O)[C@@H](CC1=CC(I)=CC=C1)NC(=O)CCl ARNFNRFSPMXZAG-LDYMZIIASA-N 0.000 description 2
• BNWIEYDZOIMYMJ-JTQLQIEISA-N 2-chloro-N-[(2S)-1-hydroxy-3-(3-iodophenyl)propan-2-yl]acetamide Chemical compound ClCC(=O)N[C@@H](CC1=CC(=CC=C1)I)CO BNWIEYDZOIMYMJ-JTQLQIEISA-N 0.000 description 2
• CXYWXLUYCHDQCN-UHFFFAOYSA-N 2-fluoro-3-methyl-6-(triazol-2-yl)benzoic acid Chemical compound OC(=O)C1=C(F)C(C)=CC=C1N1N=CC=N1 CXYWXLUYCHDQCN-UHFFFAOYSA-N 0.000 description 2
• ZDZURTUFHPRITG-UHFFFAOYSA-N 3-(2-fluoro-5-iodophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC(I)=CC=C1F ZDZURTUFHPRITG-UHFFFAOYSA-N 0.000 description 2
• HKTWUZULWRUEBY-UHFFFAOYSA-N 3-[[4-chloro-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine;hydrochloride Chemical compound Cl.C1=C(C2=NOC=N2)C(Cl)=CC=C1CC1COCCN1 HKTWUZULWRUEBY-UHFFFAOYSA-N 0.000 description 2
• KYPYOTZDMHPCLT-UHFFFAOYSA-N 3-[[4-methyl-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine;hydrochloride Chemical compound Cl.C1=C(C2=NOC=N2)C(C)=CC=C1CC1COCCN1 KYPYOTZDMHPCLT-UHFFFAOYSA-N 0.000 description 2
• BYTQKOCSGGRTSI-UHFFFAOYSA-N 3-bromopyridazin-1-ium;bromide Chemical compound Br.BrC1=CC=CN=N1 BYTQKOCSGGRTSI-UHFFFAOYSA-N 0.000 description 2
• IBQJAAIBLGSGSO-UHFFFAOYSA-N 3-methyl-2-(triazol-2-yl)benzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1N1N=CC=N1 IBQJAAIBLGSGSO-UHFFFAOYSA-N 0.000 description 2
• GPRNFRKRRJNJHJ-UHFFFAOYSA-N 3-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C=1C=CC(N2N=CC=N2)=CC=1CC1(C)COCCN1 GPRNFRKRRJNJHJ-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
• YHPJTKZGZAVEIL-UHFFFAOYSA-N 5-[(3-iodophenyl)methyl]-5-methylmorpholin-3-one Chemical compound C=1C=CC(I)=CC=1CC1(C)COCC(=O)N1 YHPJTKZGZAVEIL-UHFFFAOYSA-N 0.000 description 2
• NBUCTPRBIWLUEC-UHFFFAOYSA-N 5-chloro-4-methyl-2-(triazol-2-yl)benzoic acid Chemical compound C1=C(Cl)C(C)=CC(N2N=CC=N2)=C1C(O)=O NBUCTPRBIWLUEC-UHFFFAOYSA-N 0.000 description 2
• SRBAGFIYKNQXDV-UHFFFAOYSA-N 5-methyl-2-(triazol-2-yl)benzoic acid Chemical compound OC(=O)C1=CC(C)=CC=C1N1N=CC=N1 SRBAGFIYKNQXDV-UHFFFAOYSA-N 0.000 description 2
• CJVLMNWLOGOOGB-UHFFFAOYSA-N 5-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound C=1C=CC(N2N=CC=N2)=CC=1CC1(C)COCC(=O)N1 CJVLMNWLOGOOGB-UHFFFAOYSA-N 0.000 description 2
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
• 208000000103 Anorexia Nervosa Diseases 0.000 description 2
• 206010004716 Binge eating Diseases 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
• 206010012289 Dementia Diseases 0.000 description 2
• 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
• ZAIFGYFUWQAJLP-KKLWWLSJSA-N IC=1C=C(C[C@H]2N(CCOC2)C=2C(=C(C=C(C2)C)C(=O)C2=C(C(=CC(=C2)C)N2[C@@H](COCC2)CC2=CC(=CC=C2)I)N2N=CC=N2)N2N=CC=N2)C=CC1 Chemical compound IC=1C=C(C[C@H]2N(CCOC2)C=2C(=C(C=C(C2)C)C(=O)C2=C(C(=CC(=C2)C)N2[C@@H](COCC2)CC2=CC(=CC=C2)I)N2N=CC=N2)N2N=CC=N2)C=CC1 ZAIFGYFUWQAJLP-KKLWWLSJSA-N 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 102000003797 Neuropeptides Human genes 0.000 description 2
• 108090000189 Neuropeptides Proteins 0.000 description 2
• 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 description 2
• GEYBMYRBIABFTA-VIFPVBQESA-N O-methyl-L-tyrosine Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1 GEYBMYRBIABFTA-VIFPVBQESA-N 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 206010033664 Panic attack Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 206010034912 Phobia Diseases 0.000 description 2
• 208000001431 Psychomotor Agitation Diseases 0.000 description 2
• 208000028017 Psychotic disease Diseases 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• 206010038743 Restlessness Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 206010041250 Social phobia Diseases 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• XQVBRJNCDIVASH-MRXNPFEDSA-N [(3R)-3-[(3-iodo-4-methoxyphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound IC=1C=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=CC1OC XQVBRJNCDIVASH-MRXNPFEDSA-N 0.000 description 2
• ONVKTAGSXCPXIK-LJQANCHMSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)Cl)C(C=1)=CC=CC=1N1N=CC=N1 ONVKTAGSXCPXIK-LJQANCHMSA-N 0.000 description 2
• 230000006389 acute stress response Effects 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 208000022531 anorexia Diseases 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 230000004596 appetite loss Effects 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 238000006555 catalytic reaction Methods 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 238000007596 consolidation process Methods 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 206010061428 decreased appetite Diseases 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 230000035622 drinking Effects 0.000 description 2
• 230000019439 energy homeostasis Effects 0.000 description 2
• 206010015037 epilepsy Diseases 0.000 description 2
• 230000001073 episodic memory Effects 0.000 description 2
• 230000004634 feeding behavior Effects 0.000 description 2
• 239000012065 filter cake Substances 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 150000003840 hydrochlorides Chemical class 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 210000003016 hypothalamus Anatomy 0.000 description 2
• 150000002466 imines Chemical class 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 229960003299 ketamine Drugs 0.000 description 2
• 210000001853 liver microsome Anatomy 0.000 description 2
• 208000019017 loss of appetite Diseases 0.000 description 2
• 235000021266 loss of appetite Nutrition 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 208000004296 neuralgia Diseases 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 208000021722 neuropathic pain Diseases 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• OHOWSYIKESXDMN-WMQZXSDYSA-N orexin-b Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)C1=CNC=N1 OHOWSYIKESXDMN-WMQZXSDYSA-N 0.000 description 2
• KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
• 208000019906 panic disease Diseases 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 208000023515 periodic limb movement disease Diseases 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000000241 respiratory effect Effects 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 201000002859 sleep apnea Diseases 0.000 description 2
• 230000008454 sleep-wake cycle Effects 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 201000009032 substance abuse Diseases 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• NVOACJCZJBLHSW-OAHLLOKOSA-N tert-butyl (3R)-3-[(3-cyano-4-methoxyphenyl)methyl]morpholine-4-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](COCC1)CC1=CC(=C(C=C1)OC)C#N NVOACJCZJBLHSW-OAHLLOKOSA-N 0.000 description 2
• YEFYTWNFRQZKCB-OAHLLOKOSA-N tert-butyl (3R)-3-[(3-cyanophenyl)methyl]morpholine-4-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](COCC1)CC1=CC(=CC=C1)C#N YEFYTWNFRQZKCB-OAHLLOKOSA-N 0.000 description 2
• IPBNBCUNEZYQCS-CYBMUJFWSA-N tert-butyl (3R)-3-[(3-iodo-4-methoxyphenyl)methyl]morpholine-4-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](COCC1)CC1=CC(=C(C=C1)OC)I IPBNBCUNEZYQCS-CYBMUJFWSA-N 0.000 description 2
• MBGOPDXJAKYNOH-OAHLLOKOSA-N tert-butyl (3R)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine-4-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](COCC1)CC1=CC(=CC=C1)C1=NOC=N1 MBGOPDXJAKYNOH-OAHLLOKOSA-N 0.000 description 2
• DEHYOXSRLODULD-QGZVFWFLSA-N tert-butyl (3r)-3-[(3-pyrimidin-2-ylphenyl)methyl]morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOC[C@H]1CC1=CC=CC(C=2N=CC=CN=2)=C1 DEHYOXSRLODULD-QGZVFWFLSA-N 0.000 description 2
• AEPFJOKWEXQFFJ-CQSZACIVSA-N tert-butyl (3r)-3-[[4-methoxy-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine-4-carboxylate Chemical compound C1=C(C2=NOC=N2)C(OC)=CC=C1C[C@@H]1COCCN1C(=O)OC(C)(C)C AEPFJOKWEXQFFJ-CQSZACIVSA-N 0.000 description 2
• 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 2
• 125000004950 trifluoroalkyl group Chemical group 0.000 description 2
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
• SSMQECSVMNPOLS-SSDOTTSWSA-N (2R)-1-(3-iodophenyl)propan-2-amine Chemical compound C[C@@H](N)Cc1cccc(I)c1 SSMQECSVMNPOLS-SSDOTTSWSA-N 0.000 description 1
• DNLURDSCELRCIK-LBPRGKRZSA-N (2S)-2-[[3-(triazol-2-yl)phenyl]methyl]pyrrolidine-1-carboxylic acid Chemical compound N=1N(N=CC=1)C=1C=C(C[C@H]2N(CCC2)C(=O)O)C=CC=1 DNLURDSCELRCIK-LBPRGKRZSA-N 0.000 description 1
• ZSAIHAKADPJIGN-LBPRGKRZSA-N (2s)-1-phenylmethoxycarbonylpiperidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCCN1C(=O)OCC1=CC=CC=C1 ZSAIHAKADPJIGN-LBPRGKRZSA-N 0.000 description 1
• UPTZBFZYNZFJEN-LURJTMIESA-N (2s)-2-(hydroxymethyl)piperidine-1-carboxylic acid Chemical compound OC[C@@H]1CCCCN1C(O)=O UPTZBFZYNZFJEN-LURJTMIESA-N 0.000 description 1
• MPTBEGFNTNOLNZ-NSHDSACASA-N (2s)-3-(3-iodophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC(I)=C1 MPTBEGFNTNOLNZ-NSHDSACASA-N 0.000 description 1
• LBXCDFQUXUGIFR-XQRIHRDZSA-N (2s,3r)-3-amino-4-(3-iodophenyl)butan-2-ol;hydrochloride Chemical compound Cl.C[C@H](O)[C@H](N)CC1=CC=CC(I)=C1 LBXCDFQUXUGIFR-XQRIHRDZSA-N 0.000 description 1
• NDOUDTBXCRRZRI-ZWNOBZJWSA-N (5R,6R)-6-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound C[C@H]1OCC(N[C@@H]1CC1=CC(=CC=C1)N1N=CC=N1)=O NDOUDTBXCRRZRI-ZWNOBZJWSA-N 0.000 description 1
• LIKPAVQDIRETPJ-GZMMTYOYSA-N (5R,6S)-5-[(3-iodophenyl)methyl]-6-methylmorpholin-3-one Chemical compound IC=1C=C(C[C@@H]2[C@@H](OCC(N2)=O)C)C=CC1 LIKPAVQDIRETPJ-GZMMTYOYSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
• AXTPKYQMUDUCFW-UHFFFAOYSA-N 1,3-thiazole 1,1-dioxide Chemical compound O=S1(=O)C=CN=C1 AXTPKYQMUDUCFW-UHFFFAOYSA-N 0.000 description 1
• BACZSVQZBSCWIG-UHFFFAOYSA-N 1-(bromomethyl)-3-iodobenzene Chemical compound BrCC1=CC=CC(I)=C1 BACZSVQZBSCWIG-UHFFFAOYSA-N 0.000 description 1
• 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
• 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
• MDCITLDBLKRONS-UHFFFAOYSA-N 2-(2-methylphenyl)triazole Chemical compound CC1=CC=CC=C1N1N=CC=N1 MDCITLDBLKRONS-UHFFFAOYSA-N 0.000 description 1
• KDDPMKJRRPHLTE-UHFFFAOYSA-N 2-amino-2-[(2-methylpropan-2-yl)oxycarbonyl]propanedioic acid Chemical compound CC(C)(C)OC(=O)C(N)(C(O)=O)C(O)=O KDDPMKJRRPHLTE-UHFFFAOYSA-N 0.000 description 1
• VPNWKPSTJOTTHA-UHFFFAOYSA-N 2-bromo-3,5-dimethylbenzoic acid Chemical compound CC1=CC(C)=C(Br)C(C(O)=O)=C1 VPNWKPSTJOTTHA-UHFFFAOYSA-N 0.000 description 1
• ATBGJJWZVUNYOV-UHFFFAOYSA-N 2-bromo-4-chloro-5-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=C(Br)C=C1Cl ATBGJJWZVUNYOV-UHFFFAOYSA-N 0.000 description 1
• HECJSMILDFGZPA-UHFFFAOYSA-N 2-bromo-4-fluoro-5-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=C(Br)C=C1F HECJSMILDFGZPA-UHFFFAOYSA-N 0.000 description 1
• BFPGCWOVXJFKPY-UHFFFAOYSA-N 2-bromo-5-methoxy-4-methylbenzoic acid Chemical compound COC1=CC(C(O)=O)=C(Br)C=C1C BFPGCWOVXJFKPY-UHFFFAOYSA-N 0.000 description 1
• ARNFNRFSPMXZAG-GZMMTYOYSA-N 2-chloro-N-[(2R,3S)-3-hydroxy-1-(3-iodophenyl)butan-2-yl]acetamide Chemical compound ClCC(=O)N[C@@H]([C@H](C)O)CC1=CC(=CC=C1)I ARNFNRFSPMXZAG-GZMMTYOYSA-N 0.000 description 1
• GUPOZVHRTJYZCX-UHFFFAOYSA-N 2-chloroethanimidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])CCl GUPOZVHRTJYZCX-UHFFFAOYSA-N 0.000 description 1
• URAWWWSOINMMIO-UHFFFAOYSA-N 2-chloroethylhydrazine Chemical class NNCCCl URAWWWSOINMMIO-UHFFFAOYSA-N 0.000 description 1
• LPIDQLZQEGPBCO-UHFFFAOYSA-N 2-chloropyridine;hydrochloride Chemical compound Cl.ClC1=CC=CC=N1 LPIDQLZQEGPBCO-UHFFFAOYSA-N 0.000 description 1
• KBFVSJVSSMGQJC-UHFFFAOYSA-N 2-fluoro-3-methylbenzonitrile Chemical compound CC1=CC=CC(C#N)=C1F KBFVSJVSSMGQJC-UHFFFAOYSA-N 0.000 description 1
• QNNJHBNTHVHALE-UHFFFAOYSA-N 2-fluoro-5-iodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC=C1F QNNJHBNTHVHALE-UHFFFAOYSA-N 0.000 description 1
• XYRLGIOIAJNDJX-UHFFFAOYSA-N 2-fluoro-6-iodo-3-methylbenzoic acid Chemical compound CC1=CC=C(I)C(C(O)=O)=C1F XYRLGIOIAJNDJX-UHFFFAOYSA-N 0.000 description 1
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• CGUFWPQURMBLMB-UHFFFAOYSA-N 2-iodo-3-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=CC(C#N)=C1I CGUFWPQURMBLMB-UHFFFAOYSA-N 0.000 description 1
• YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
• UMVOQQDNEYOJOK-UHFFFAOYSA-N 3,5-dimethylbenzoic acid Chemical compound CC1=CC(C)=CC(C(O)=O)=C1 UMVOQQDNEYOJOK-UHFFFAOYSA-N 0.000 description 1
• VLRGXXKFHVJQOL-UHFFFAOYSA-N 3-chloropentane-2,4-dione Chemical compound CC(=O)C(Cl)C(C)=O VLRGXXKFHVJQOL-UHFFFAOYSA-N 0.000 description 1
• 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 1
• CEAVPXDEPGAVDA-UHFFFAOYSA-N 3-methoxy-4-methylbenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1C CEAVPXDEPGAVDA-UHFFFAOYSA-N 0.000 description 1
• ZABRUMFAJKMYDU-UHFFFAOYSA-N 3-methyl-2-(triazol-2-yl)benzonitrile Chemical compound CC1=CC=CC(C#N)=C1N1N=CC=N1 ZABRUMFAJKMYDU-UHFFFAOYSA-N 0.000 description 1
• WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
• OXUUNDMDOOXPKY-UHFFFAOYSA-N 4-chloro-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1Cl OXUUNDMDOOXPKY-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• LWGCZCMLPRMKIZ-UHFFFAOYSA-N 4-fluoro-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1F LWGCZCMLPRMKIZ-UHFFFAOYSA-N 0.000 description 1
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
• QRSUCLRXIYIEMG-UHFFFAOYSA-N 5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound N1C(=O)COCC1CC1=CC=CC(N2N=CC=N2)=C1 QRSUCLRXIYIEMG-UHFFFAOYSA-N 0.000 description 1
• 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
• 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
• 241000349731 Afzelia bipindensis Species 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
• 108010017443 B 43 Proteins 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• NSGGNQSFJMODHD-UHFFFAOYSA-N C(C)OC(C(C)(C)C1=CC(=CC=C1)I)=O Chemical compound C(C)OC(C(C)(C)C1=CC(=CC=C1)I)=O NSGGNQSFJMODHD-UHFFFAOYSA-N 0.000 description 1
• HDSSQKZNDOIIBJ-RYIVJZHSSA-N C(C)[C@@H]1CN([C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1)C(C1=C(C=CC(=C1)C)N1N=CC=N1)C(=O)C(N1C[C@H](OC[C@H]1CC1=CC(=CC=C1)N1N=CC=N1)CC)C1=C(C=CC(=C1)C)N1N=CC=N1 Chemical compound C(C)[C@@H]1CN([C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1)C(C1=C(C=CC(=C1)C)N1N=CC=N1)C(=O)C(N1C[C@H](OC[C@H]1CC1=CC(=CC=C1)N1N=CC=N1)CC)C1=C(C=CC(=C1)C)N1N=CC=N1 HDSSQKZNDOIIBJ-RYIVJZHSSA-N 0.000 description 1
• REIGRFGTWPNPEU-JGCGQSQUSA-N C(C1=CC=CC=C1)C=1C(=C(C=C(C1)CC1=CC=CC=C1)C(=O)N1[C@@H](COCC1)CC1=CC(=CC=C1)C1=NOC=N1)N1N=CC=N1 Chemical compound C(C1=CC=CC=C1)C=1C(=C(C=C(C1)CC1=CC=CC=C1)C(=O)N1[C@@H](COCC1)CC1=CC(=CC=C1)C1=NOC=N1)N1N=CC=N1 REIGRFGTWPNPEU-JGCGQSQUSA-N 0.000 description 1
• KTETVPXBWOHYCR-UHFFFAOYSA-N CC(C)(C)OC(=O)NC(Cc1ccc(Cl)c(I)c1)C(O)=O Chemical compound CC(C)(C)OC(=O)NC(Cc1ccc(Cl)c(I)c1)C(O)=O KTETVPXBWOHYCR-UHFFFAOYSA-N 0.000 description 1
• ARWXLGINGFFVKT-JWLNASMESA-N CC1=C(C[C@H]2N(CCOC2)C(C2=C(C=C(C=C2)C)N2N=CC=N2)C(=O)C(N2[C@@H](COCC2)CC2=C(C=CC(=C2)N2N=CC=C2)C)C2=C(C=C(C=C2)C)N2N=CC=N2)C=C(C=C1)N1N=CC=C1 Chemical compound CC1=C(C[C@H]2N(CCOC2)C(C2=C(C=C(C=C2)C)N2N=CC=N2)C(=O)C(N2[C@@H](COCC2)CC2=C(C=CC(=C2)N2N=CC=C2)C)C2=C(C=C(C=C2)C)N2N=CC=N2)C=C(C=C1)N1N=CC=C1 ARWXLGINGFFVKT-JWLNASMESA-N 0.000 description 1
• RAYHEEMEFVQOIO-LJQANCHMSA-N COC1=C(C=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C1)C=1NOC=CC1 Chemical compound COC1=C(C=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C1)C=1NOC=CC1 RAYHEEMEFVQOIO-LJQANCHMSA-N 0.000 description 1
• JLPZPTFGWDLADA-IILWTAMNSA-N COC1=CC(=C(C=C1)C(N1[C@@H](COCC1)CC1=CC(=CC=C1)N1N=CC=N1)C(=O)C(C1=C(C=C(C=C1)OC)N1N=CC=N1)N1[C@@H](COCC1)CC1=CC(=CC=C1)N1N=CC=N1)N1N=CC=N1 Chemical compound COC1=CC(=C(C=C1)C(N1[C@@H](COCC1)CC1=CC(=CC=C1)N1N=CC=N1)C(=O)C(C1=C(C=C(C=C1)OC)N1N=CC=N1)N1[C@@H](COCC1)CC1=CC(=CC=C1)N1N=CC=N1)N1N=CC=N1 JLPZPTFGWDLADA-IILWTAMNSA-N 0.000 description 1
• QQXYZHKPOQGNKW-HHHXNRCGSA-N COC=1C(=CC=C(CC=2C(=C(C=CC2)C(=O)N2[C@@H](COCC2)CC2=CC(=CC=C2)N2N=CC=N2)N2N=CC=N2)C1)C Chemical compound COC=1C(=CC=C(CC=2C(=C(C=CC2)C(=O)N2[C@@H](COCC2)CC2=CC(=CC=C2)N2N=CC=N2)N2N=CC=N2)C1)C QQXYZHKPOQGNKW-HHHXNRCGSA-N 0.000 description 1
• SLCXWSKFMZHODF-HVQZGMPCSA-N C[C@@H]1N([C@@H](COC1)CC1=CC(=CC=C1)N1N=CC=N1)C=1C(=C(C=C(C1)C)C(=O)C1=C(C(=CC(=C1)C)N1[C@H](COC[C@H]1CC1=CC(=CC=C1)N1N=CC=N1)C)N1N=CC=N1)N1N=CC=N1 Chemical compound C[C@@H]1N([C@@H](COC1)CC1=CC(=CC=C1)N1N=CC=N1)C=1C(=C(C=C(C1)C)C(=O)C1=C(C(=CC(=C1)C)N1[C@H](COC[C@H]1CC1=CC(=CC=C1)N1N=CC=N1)C)N1N=CC=N1)N1N=CC=N1 SLCXWSKFMZHODF-HVQZGMPCSA-N 0.000 description 1
• 244000025254 Cannabis sativa Species 0.000 description 1
• 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
• 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• OOWBFKDKNPQJFU-UHFFFAOYSA-N Cc1ccc(CC(NC(=O)OC(C)(C)C)C(O)=O)cc1I Chemical compound Cc1ccc(CC(NC(=O)OC(C)(C)C)C(O)=O)cc1I OOWBFKDKNPQJFU-UHFFFAOYSA-N 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
• 206010011971 Decreased interest Diseases 0.000 description 1
• MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
• 206010012239 Delusion Diseases 0.000 description 1
• 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
• WLTCKEHCTUYJGI-UHFFFAOYSA-N Diethyl aminomalonate Chemical compound CCOC(=O)C(N)C(=O)OCC WLTCKEHCTUYJGI-UHFFFAOYSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• SMUHIWZRLGWZDW-BPJZXZEESA-N FC1=C(C[C@@H]2CO[C@@H](CN2C(C2=C(C=CC=C2)N2N=CC=N2)C(=O)C(N2C[C@H](OC[C@H]2CC2=C(C=CC(=C2)N2N=CC=N2)F)C)C2=C(C=CC=C2)N2N=CC=N2)C)C=C(C=C1)N1N=CC=N1 Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C(C2=C(C=CC=C2)N2N=CC=N2)C(=O)C(N2C[C@H](OC[C@H]2CC2=C(C=CC(=C2)N2N=CC=N2)F)C)C2=C(C=CC=C2)N2N=CC=N2)C)C=C(C=C1)N1N=CC=N1 SMUHIWZRLGWZDW-BPJZXZEESA-N 0.000 description 1
• ZNBDSQVVVCQIBV-JUTABEQOSA-N FC1=C(C[C@@H]2CO[C@@H](CN2C2=C(C(=C(C=C2)C(=O)C2=C(C(=C(C=C2)N2C[C@H](OC[C@H]2CC2=C(C=CC(=C2)N2N=CC=N2)F)C)C)N2N=CC=N2)N2N=CC=N2)C)C)C=C(C=C1)N1N=CC=N1 Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C2=C(C(=C(C=C2)C(=O)C2=C(C(=C(C=C2)N2C[C@H](OC[C@H]2CC2=C(C=CC(=C2)N2N=CC=N2)F)C)C)N2N=CC=N2)N2N=CC=N2)C)C)C=C(C=C1)N1N=CC=N1 ZNBDSQVVVCQIBV-JUTABEQOSA-N 0.000 description 1
• 208000018460 Feeding disease Diseases 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 208000001613 Gambling Diseases 0.000 description 1
• 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
• 101000598921 Homo sapiens Orexin Proteins 0.000 description 1
• 101500025902 Homo sapiens Orexin-A Proteins 0.000 description 1
• LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
• 206010020710 Hyperphagia Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
• 239000005909 Kieselgur Substances 0.000 description 1
• 208000009829 Lewy Body Disease Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 208000036626 Mental retardation Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
• QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
• PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
• GQNRBSHDASJAJZ-XPSQVAKYSA-N N1=C(N=CC=C1)C=1C=C(C[C@H]2N(CCOC2)C=2C(=C(C=CC2)C(=O)C2=C(C(=CC=C2)N2[C@@H](COCC2)CC2=CC(=CC=C2)C2=NC=CC=N2)N2N=CC=N2)N2N=CC=N2)C=CC1 Chemical compound N1=C(N=CC=C1)C=1C=C(C[C@H]2N(CCOC2)C=2C(=C(C=CC2)C(=O)C2=C(C(=CC=C2)N2[C@@H](COCC2)CC2=CC(=CC=C2)C2=NC=CC=N2)N2N=CC=N2)N2N=CC=N2)C=CC1 GQNRBSHDASJAJZ-XPSQVAKYSA-N 0.000 description 1
• 229910019065 NaOH 1 M Inorganic materials 0.000 description 1
• 102000028517 Neuropeptide receptor Human genes 0.000 description 1
• 108070000018 Neuropeptide receptor Proteins 0.000 description 1
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
• ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
• 208000000224 Night Terrors Diseases 0.000 description 1
• 206010029412 Nightmare Diseases 0.000 description 1
• GEYBMYRBIABFTA-SECBINFHSA-N O-methyl-D-tyrosine Chemical compound COC1=CC=C(C[C@@H]([NH3+])C([O-])=O)C=C1 GEYBMYRBIABFTA-SECBINFHSA-N 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 101150053185 P450 gene Proteins 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 229940083963 Peptide antagonist Drugs 0.000 description 1
• 206010034374 Perception disturbances Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 208000005793 Restless legs syndrome Diseases 0.000 description 1
• 208000000810 Separation Anxiety Diseases 0.000 description 1
• 206010041010 Sleep terror Diseases 0.000 description 1
• 208000022249 Sleep-Wake Transition disease Diseases 0.000 description 1
• 206010041235 Snoring Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 206010041347 Somnambulism Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• RRSNAFVMJVWFGD-NHCUHLMSSA-N [(2R,5R)-2-ethyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound CC[C@@H]1CN([C@H](Cc2cccc(c2)-n2nccn2)CO1)C(=O)c1ccccc1-n1nccn1 RRSNAFVMJVWFGD-NHCUHLMSSA-N 0.000 description 1
• QDURYEZFCXJVOM-DENIHFKCSA-N [(2R,5R)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C[C@@H]1CN([C@@H](CO1)CC1=CC(=CC=C1)C1=NC=CC=N1)C(=O)C1=C(C(=CC=C1)C)N1N=CC=N1 QDURYEZFCXJVOM-DENIHFKCSA-N 0.000 description 1
• STINWRWRNQHPGO-DENIHFKCSA-N [(2R,5R)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C[C@@H]1CN([C@@H](CO1)CC1=CC(=CC=C1)C1=NC=CC=N1)C(=O)C1=C(C=C(C=C1)C)N1N=CC=N1 STINWRWRNQHPGO-DENIHFKCSA-N 0.000 description 1
• STUGMTDSOKPRBQ-WIYYLYMNSA-N [(2R,5R)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C[C@@H]1CN([C@H](Cc2cc(ccc2F)-c2ncccn2)CO1)C(=O)c1cccc(C)c1-n1nccn1 STUGMTDSOKPRBQ-WIYYLYMNSA-N 0.000 description 1
• HYSRABRBUHZYQJ-WIYYLYMNSA-N [(2R,5R)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C(=O)C2=C(C=C(C=C2)C)N2N=CC=N2)C)C=C(C=C1)C1=NC=CC=N1 HYSRABRBUHZYQJ-WIYYLYMNSA-N 0.000 description 1
• AEIDDRZWBROWDG-WIYYLYMNSA-N [(2R,5R)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C(=O)C2=C(C=CC(=C2)C)N2N=CC=N2)C)C=C(C=C1)C1=NC=CC=N1 AEIDDRZWBROWDG-WIYYLYMNSA-N 0.000 description 1
• SNOAPCQTEZAFRK-VQIMIIECSA-N [(2R,5R)-5-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]-2-methylmorpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C(=O)C2=C(C=CC=C2)N2N=CC=N2)C)C=C(C=C1)N1N=CC=N1 SNOAPCQTEZAFRK-VQIMIIECSA-N 0.000 description 1
• QWFXFQGJPGRBQR-YLJYHZDGSA-N [(2r,5r)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 QWFXFQGJPGRBQR-YLJYHZDGSA-N 0.000 description 1
• PRAYXGYYVXRDDW-LURJTMIESA-N [(2s)-piperidin-2-yl]methanol Chemical compound OC[C@@H]1CCCCN1 PRAYXGYYVXRDDW-LURJTMIESA-N 0.000 description 1
• OGEMHFJULYOBHG-QGZVFWFLSA-N [(3R)-3-[(3-iodophenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound IC=1C=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=CC1 OGEMHFJULYOBHG-QGZVFWFLSA-N 0.000 description 1
• UZGKFZMOPJQKAA-QGZVFWFLSA-N [(3R)-3-[(4-methoxyphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound COC1=CC=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C1 UZGKFZMOPJQKAA-QGZVFWFLSA-N 0.000 description 1
• FIPXBPYXRCPALA-LJQANCHMSA-N [(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(ccc2Cl)-n2nccn2)c1-n1nccn1 FIPXBPYXRCPALA-LJQANCHMSA-N 0.000 description 1
• YNLXALPSUPUEOW-GOSISDBHSA-N [(3R)-3-[[2-fluoro-3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=C(C=C2)C)N2N=CC=N2)C=CC=C1N1N=CC=N1 YNLXALPSUPUEOW-GOSISDBHSA-N 0.000 description 1
• QIKVTMHZHYXNDE-HXUWFJFHSA-N [(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 QIKVTMHZHYXNDE-HXUWFJFHSA-N 0.000 description 1
• OQWDRLJUBNCFEY-GOSISDBHSA-N [(3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=CC=C(C=1N1N=CC=N1)C)C(C(=CC=1)F)=CC=1C=1N=CON=1 OQWDRLJUBNCFEY-GOSISDBHSA-N 0.000 description 1
• WXVVKTBDFXUAHG-OAQYLSRUSA-N [(3r)-3-[[3-(4-methylpyrimidin-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC=NC(C=2C=C(C[C@H]3N(CCOC3)C(=O)C=3C(=CC=CC=3)N3N=CC=N3)C=CC=2)=N1 WXVVKTBDFXUAHG-OAQYLSRUSA-N 0.000 description 1
• CMSWWEXLVMHQNL-GOSISDBHSA-N [(3r)-3-[[4-methoxy-3-(1,3-thiazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2SC=CN=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 CMSWWEXLVMHQNL-GOSISDBHSA-N 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• OFOKYTZDYMGETB-SFHVURJKSA-N [2-(triazol-2-yl)phenyl]-[(2s)-2-[[3-(triazol-2-yl)phenyl]methyl]pyrrolidin-1-yl]methanone Chemical compound C([C@@H]1CCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 OFOKYTZDYMGETB-SFHVURJKSA-N 0.000 description 1
• HCNLIVZSGOZAEH-IBGZPJMESA-N [2-(triazol-2-yl)phenyl]-[(3s)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 HCNLIVZSGOZAEH-IBGZPJMESA-N 0.000 description 1
• SWDMQWHTMPUUHA-XMSQKQJNSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(2r,5r)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=C(C)C(C)=CC=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 SWDMQWHTMPUUHA-XMSQKQJNSA-N 0.000 description 1
• DADWYMXJDHTELJ-LJQANCHMSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C(=C1N1N=CC=N1)C)C)C(C(=CC=1)F)=CC=1C=1N=CON=1 DADWYMXJDHTELJ-LJQANCHMSA-N 0.000 description 1
• YLJVEPVMPPEJBJ-VQIMIIECSA-N [3-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=C(Cl)C=CC=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 YLJVEPVMPPEJBJ-VQIMIIECSA-N 0.000 description 1
• BQVDTYWMMKIXOA-GOSISDBHSA-N [3-fluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=CC=C(C=1N1N=CC=N1)F)C(C=1)=CC=CC=1N1N=CC=N1 BQVDTYWMMKIXOA-GOSISDBHSA-N 0.000 description 1
• HMJZZKHOLAJQCJ-PGRDOPGGSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(2S,3R)-2-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C[C@H]1[C@H](N(CCO1)C(=O)C1=C(C(=CC=C1)C)N1N=CC=N1)CC1=CC(=CC=C1)N1N=CC=N1 HMJZZKHOLAJQCJ-PGRDOPGGSA-N 0.000 description 1
• WRLVGTRMEZGZFE-WIYYLYMNSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=C(C)C=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 WRLVGTRMEZGZFE-WIYYLYMNSA-N 0.000 description 1
• UGPJDNRZMHMMDB-LJQANCHMSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=CC=C(C=1N1N=CC=N1)C)C(C=1)=CC=CC=1C=1N=CON=1 UGPJDNRZMHMMDB-LJQANCHMSA-N 0.000 description 1
• BTNLZELUPKRKLO-HXUWFJFHSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)C)C)C(C=1)=CC=CC=1C=1N=CON=1 BTNLZELUPKRKLO-HXUWFJFHSA-N 0.000 description 1
• IUBQIPSNLRGHJH-GOSISDBHSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)Cl)C(C=1)=CC=CC=1C=1N=CON=1 IUBQIPSNLRGHJH-GOSISDBHSA-N 0.000 description 1
• XDAZJJGYLDZHNW-WIYYLYMNSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 XDAZJJGYLDZHNW-WIYYLYMNSA-N 0.000 description 1
• XDAZJJGYLDZHNW-GHTZIAJQSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(2s,5r)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@@H](OC1)C)C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 XDAZJJGYLDZHNW-GHTZIAJQSA-N 0.000 description 1
• WYFQHYNFGVNXFG-OAQYLSRUSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C=1)=CC=CC=1N1C=CC=N1 WYFQHYNFGVNXFG-OAQYLSRUSA-N 0.000 description 1
• KKGJPPRCCVZKMV-DYESRHJHSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC=C(Cl)C=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 KKGJPPRCCVZKMV-DYESRHJHSA-N 0.000 description 1
• LFTFHZCWXHYQAL-LJQANCHMSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)C=2N=CC=CN=2)OCCN1C(=O)C1=CC(Cl)=CC=C1N1N=CC=N1 LFTFHZCWXHYQAL-LJQANCHMSA-N 0.000 description 1
• GOPNUSXTFNCXKO-QGZVFWFLSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)C2=NOC=N2)OCCN1C(=O)C1=CC(Cl)=CC=C1N1N=CC=N1 GOPNUSXTFNCXKO-QGZVFWFLSA-N 0.000 description 1
• CLOOLVHJLDFMDV-LJQANCHMSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)Cl)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 CLOOLVHJLDFMDV-LJQANCHMSA-N 0.000 description 1
• TVALGRAHOLPKKR-GOSISDBHSA-N [5-fluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)F)N1N=CC=N1)C(C=1)=CC=CC=1C=1N=CON=1 TVALGRAHOLPKKR-GOSISDBHSA-N 0.000 description 1
• GEVLHZAYQOXANJ-HXUWFJFHSA-N [5-methoxy-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)OC)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 GEVLHZAYQOXANJ-HXUWFJFHSA-N 0.000 description 1
• VYUBRYYCCNWARR-FQEVSTJZSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(2s)-2-[[3-(triazol-2-yl)phenyl]methyl]piperidin-1-yl]methanone Chemical compound C([C@@H]1CCCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 VYUBRYYCCNWARR-FQEVSTJZSA-N 0.000 description 1
• PQIZGRDRKSOBSA-IBGZPJMESA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(2s)-2-[[3-(triazol-2-yl)phenyl]methyl]pyrrolidin-1-yl]methanone Chemical compound C([C@@H]1CCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 PQIZGRDRKSOBSA-IBGZPJMESA-N 0.000 description 1
• AOBDPAOQKBBOMZ-XMMPIXPASA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3R)-3-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C[C@@]1(N(CCOC1)C(=O)C1=C(C=CC(=C1)C)N1N=CC=N1)CC1=CC(=CC=C1)N1N=CC=N1 AOBDPAOQKBBOMZ-XMMPIXPASA-N 0.000 description 1
• QZXHCJASGVSEHH-OAQYLSRUSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyridazin-3-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=CC=CN=N1 QZXHCJASGVSEHH-OAQYLSRUSA-N 0.000 description 1
• JHOLYWCJSQKKLV-OAQYLSRUSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 JHOLYWCJSQKKLV-OAQYLSRUSA-N 0.000 description 1
• ZGEVFIAJYRECKD-HXUWFJFHSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,3-thiazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CS1 ZGEVFIAJYRECKD-HXUWFJFHSA-N 0.000 description 1
• ZFYSWSAVTSDYNI-HXUWFJFHSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-1-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1C=CN=N1 ZFYSWSAVTSDYNI-HXUWFJFHSA-N 0.000 description 1
• FUOSTXPWTMZICG-LJQANCHMSA-N [6-methyl-3-(triazol-2-yl)pyridin-2-yl]-[(3R)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound CC1=CC=C(C(=N1)C(=O)N1[C@@H](COCC1)CC1=CC(=CC=C1)N1N=CC=N1)N1N=CC=N1 FUOSTXPWTMZICG-LJQANCHMSA-N 0.000 description 1
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 208000026345 acute stress disease Diseases 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 208000029650 alcohol withdrawal Diseases 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 230000001430 anti-depressive effect Effects 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 238000013528 artificial neural network Methods 0.000 description 1
• 230000035045 associative learning Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 210000003403 autonomic nervous system Anatomy 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• TUWZZXGAUMSUOB-UHFFFAOYSA-N benzyl piperidine-1-carboxylate Chemical compound C1CCCCN1C(=O)OCC1=CC=CC=C1 TUWZZXGAUMSUOB-UHFFFAOYSA-N 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 208000028683 bipolar I disease Diseases 0.000 description 1
• 208000022257 bipolar II disease Diseases 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 238000011088 calibration curve Methods 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• GUPWNYUKYICHQX-UHFFFAOYSA-N carbonobromidic acid Chemical compound OC(Br)=O GUPWNYUKYICHQX-UHFFFAOYSA-N 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000012320 chlorinating reagent Substances 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 230000037326 chronic stress Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 235000019788 craving Nutrition 0.000 description 1
• 238000009109 curative therapy Methods 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000004665 defense response Effects 0.000 description 1
• 239000012024 dehydrating agents‎ Substances 0.000 description 1
• 231100000868 delusion Toxicity 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 230000000994 depressogenic effect Effects 0.000 description 1
• 125000004431 deuterium atom Chemical group 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 229960002069 diamorphine Drugs 0.000 description 1
• 239000002027 dichloromethane extract Substances 0.000 description 1
• 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
• WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 206010013663 drug dependence Diseases 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 235000005686 eating Nutrition 0.000 description 1
• 230000020595 eating behavior Effects 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 230000004970 emotional disturbance Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• JCXLZWMDXJFOOI-UHFFFAOYSA-N ethyl 2-aminopropanoate;hydron;chloride Chemical compound [Cl-].CCOC(=O)C(C)[NH3+] JCXLZWMDXJFOOI-UHFFFAOYSA-N 0.000 description 1
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 230000008713 feedback mechanism Effects 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 210000002454 frontal bone Anatomy 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 230000028252 learning or memory Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
• 208000020442 loss of weight Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 230000006386 memory function Effects 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• 230000003818 metabolic dysfunction Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• AYHCWHCWQSWWRE-UHFFFAOYSA-N methyl 2-bromo-5-chloro-4-methylbenzoate Chemical compound COC(=O)C1=CC(Cl)=C(C)C=C1Br AYHCWHCWQSWWRE-UHFFFAOYSA-N 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 241000514897 mixed subtypes Species 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000006855 networking Effects 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 229960001783 nicardipine Drugs 0.000 description 1
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 230000021363 nonassociative learning Effects 0.000 description 1
• 210000001009 nucleus accumben Anatomy 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 229940125636 orexin 1 receptor antagonist Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 235000020830 overeating Nutrition 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 235000019629 palatability Nutrition 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 238000005191 phase separation Methods 0.000 description 1
• 230000010363 phase shift Effects 0.000 description 1
• 208000019899 phobic disease Diseases 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 206010036067 polydipsia Diseases 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
• 229960003081 probenecid Drugs 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000004129 prosencephalon Anatomy 0.000 description 1
• JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical group C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000003938 response to stress Effects 0.000 description 1
• 238000006798 ring closing metathesis reaction Methods 0.000 description 1
• 238000007142 ring opening reaction Methods 0.000 description 1
• DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 208000025874 separation anxiety disease Diseases 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 208000020685 sleep-wake disease Diseases 0.000 description 1
• 230000004037 social stress Effects 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 201000001716 specific phobia Diseases 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 231100000736 substance abuse Toxicity 0.000 description 1
• 201000006152 substance dependence Diseases 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• BYAVXGJOGRCEHB-HNNXBMFYSA-N tert-butyl (2s)-2-[(3-iodophenyl)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC[C@H]1CC1=CC=CC(I)=C1 BYAVXGJOGRCEHB-HNNXBMFYSA-N 0.000 description 1
• FIVOVOOOMFAWBY-AWEZNQCLSA-N tert-butyl (2s)-2-[(3-iodophenyl)methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CC1=CC=CC(I)=C1 FIVOVOOOMFAWBY-AWEZNQCLSA-N 0.000 description 1
• MDGBGGXDHQORJS-INIZCTEOSA-N tert-butyl (2s)-2-[[3-(triazol-2-yl)phenyl]methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC[C@H]1CC1=CC=CC(N2N=CC=N2)=C1 MDGBGGXDHQORJS-INIZCTEOSA-N 0.000 description 1
• YUNXVGBBZWRVCL-HNNXBMFYSA-N tert-butyl (2s)-2-[[3-(triazol-2-yl)phenyl]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CC1=CC=CC(N2N=CC=N2)=C1 YUNXVGBBZWRVCL-HNNXBMFYSA-N 0.000 description 1
• HJYNLENYMULSAS-UHFFFAOYSA-N tert-butyl 3-oxomorpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC1=O HJYNLENYMULSAS-UHFFFAOYSA-N 0.000 description 1
• QLGSWXOALGVOST-GXFFZTMASA-N tert-butyl N-[(2R,3S)-3-hydroxy-1-(3-iodophenyl)butan-2-yl]carbamate Chemical compound C(C)(C)(C)OC(N[C@@H]([C@H](C)O)CC1=CC(=CC=C1)I)=O QLGSWXOALGVOST-GXFFZTMASA-N 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 230000003936 working memory Effects 0.000 description 1